Euflexxa

WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD

Mon, 01 Mar 2010 15:42:38 +0000

Ferring Pharmaceuticals Announces 2010 My Little Miracle Essay Contest

PARSIPPANY, NJ – March 1, 2010 - If you are a parent who has conceived using Ferring Pharmaceuticals’ fertility products, you can win a $10,000 education fund to support your child’s future. Two other education fund prizes will also be awarded. To be eligible, all you need to do is write a brief essay. The topic is: If I Knew Then What I Know Now, explaining what advice you would give to other women who are coping with infertility and how you would describe your success using BRAVELLE^® (urofollitropin for injection, purified) and/or MENOPUR^® (menotropins for injection, USP) as part of your treatment plan.

Ferring’s My Little Miracle Essay Contest is open to women who have been successfully treated with BRAVELLE^® and/or MENOPUR^®. The contest celebrates the miracle of birth for parents who have faced infertility, and carries on Ferring’s tradition of supporting patients by offering education funds for the winners’ children.

Ferring is also awarding a $7,500 education fund to the runner-up and $5,000 to an honorable mention winner. Since announcing the first contest in 2004, Ferring has awarded $128,000 in education funds.

Essays should not exceed 2,000 words. They must be written in English, include the entrant’s name, address, phone number and age, as well as the child(ren)’s name(s) and age(s), and be submitted with a contest application and labeled digital photo. Entries must be postmarked by December 31, 2010. Winners will be announced in January 2011.

For more details and a contest application, visit www.ferringfertility.com or www.ferringusa.com or call (203) 762-8833 and ask for the My Little Miracle Essay Contest representative.

MENOPUR^® administered subcutaneously is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an ART program. BRAVELLE^® administered SC in conjunction with hCG is indicated for multiple follicular development (controlled ovarian stimulation) during ART cycles in patients who have previously received pituitary suppression. BRAVELLE^® administered SC or IM, in conjunction with hCG, is indicated for ovulation induction in patients who have previously received pituitary suppression.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe BRAVELLE^® and MENOPUR^®. BRAVELLE^® and MENOPUR^® are potent substances capable of causing mild to severe adverse reactions, including OHSS (overall incidence of 6.0% for BRAVELLE^® and 3.8% for MENOPUR^®), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. BRAVELLE^® and MENOPUR^® are contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to respectively, urofollitropins, purified, and menotropins or MENOPUR^®.

BRAVELLE^® is contraindicated for the presence of any cause of infertility other than anovulation. MENOPUR^® is contraindicated for sex hormone dependent tumors of the reproductive tract and accessory organs. BRAVELLE^® and MENOPUR^® are contraindicated in women who are pregnant. BRAVELLE^® may cause fetal harm when administered to a pregnant woman. There are limited human data on the effects of BRAVELLE^® and menotropins when administered during pregnancy.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of products in the U.S. market. They include: BRAVELLE^®, MENOPUR^® and REPRONEX^® (menotropins for injection, USP), NOVAREL^® (chorionic gonadotropin for injection, USP), ENDOMETRIN^® (progesterone) Vaginal Insert, 100 mg, FIRMAGON^® (degarelix for injection), PROSED^® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA^® (1% sodium hyaluronate). Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

Please visit www.ferringfertility.com for Full Prescribing Information for MENOPUR^® and BRAVELLE^®.

FERRING PHARMACEUTICALS AND GENE SECURITY NETWORK PARTNER TO TEST ADVANCED PREIMPLANTATION GENETIC DIAGNOSIS (PGD) TECHNOLOGY

Thu, 25 Feb 2010 23:27:18 +0000

Eleven-Center Trial to Evaluate Technology for Superior Accuracy in IVF Embryo Selection

PARSIPPANY, NJ and REDWOOD CITY, CA – February 25, 2010 – Ferring Pharmaceuticals and Gene Security Network (GSN) announced that they have signed an agreement to conduct a clinical trial of GSN’s advanced preimplantation genetic diagnosis (PGD) technology, Parental Support™. The 11-center U.S. trial is designed to evaluate if GSN’s PGD technology helps increase in vitro fertilization (IVF) success rates when using single cell embryo testing for an abnormal number of chromosomes, a condition called aneuploidy. GSN’s Parental Support technology is designed to help improve embryo selection during IVF procedures in order to increase the pregnancy rate following embryo transfer compared with IVF procedures without embryo PGD testing.

“As the market leader in innovative infertility products, we are delighted to partner with GSN to help evaluate this unique product for the fertility medical community and patients,” said Olivier Delannoy, Vice President, Infertility Business Unit at Ferring. “GSN’s technology is supported by impressive data, and may enable reproductive endocrinologists to achieve more accurate embryo selection, and hopefully lead to higher live birth rates. We are hopeful that this upcoming clinical trial will support the positive early data generated for the PGD technology.”

“Our agreement with Ferring provides the framework for our testing technology to become state of the art treatment for infertility patients. By using Parental Support to select embryos that have the best chance of developing into a healthy pregnancy, we hope to augment Ferring’s drug therapy regimen and boost pregnancy rates,” said Matthew Rabinowitz, PhD, Chief Executive Officer of Gene Security Network. “Our early data from 24-chromosome aneuploidy screening with Parental Support resulted in a 50 percent ongoing pregnancy rate for patients undergoing PGD, most of whom have had problems with previous IVF cycles. We are looking forward to initiating the prospective randomized trial in May.”

Under the terms of the agreement, every trial patient will exclusively use Ferring fertility products for their IVF cycle, receiving the medications at a discounted rate. Ferring will also provide financial support and assistance in finalizing the trial protocol and monitoring the trial’s progress, with the option to partner with GSN in distribution of Parental Support upon conclusion of the study.

About Preimplantation Genetic Diagnosis

Preimplantation genetic diagnosis (PGD) is a technique used to identify genetic defects before pregnancy in embryos created through IVF. PGD represents a means to help prevent genetic disease before implantation, thereby helping reduce the need to address the dilemma of pregnancy termination following an unfavorable prenatal diagnosis. PGD for aneuploidy refers to techniques where embryos from presumed chromosomally normal genetic parents are screened for aneuploidy. Most early pregnancy failures can be attributed to aneuploidy. Primary candidates for PGD can include: women of advanced maternal age, couples with a history of recurrent pregnancy loss, couples with repeated IVF failure, and a male partner with severe male factor infertility. The risk of aneuploidy in embryos increases as women age. The aneuploidy rate for mothers aged 35-39 years is greater than 70 percent, and is over 80 percent in mothers aged 40 years and older.¹

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com or www.ferringfertility.com.

About Gene Security Network

GSN’s proprietary Parental Support™ technology is the first to leverage data informatics to deliver highly accurate single cell testing for chromosome abnormalities and genetic diseases. Parental Support uses genetic information from the parents, as well as HapMap data from the Human Genome Project, to clarify the typically noisy measurements from a single cell and to generate an in silico reconstruction of the cell’s genotype. GSN operates a CLIA-certified laboratory in Redwood City, CA and and is supported by multiple grants from the National Institutes of Health and leading venture investors, including Claremont Creek Ventures and Sequoia Capital. For more information, please visit www.genesecurity.net.

DEGARELIX (FIRMAGON®) VS LEUPROLIDE (LUPRON DEPOT®) IN PATIENTS WITH ADVANCED PROSTATE CANCER: FURTHER ANALYSIS FROM A PHASE III PIVOTAL TRIAL

Fri, 18 Dec 2009 17:51:47 +0000

Investigators Presented Results at the Society of Urologic Oncology Annual Meeting

BETHESDA, MD – December 4, 2009 – Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III pivotal study of FIRMAGON^® (monthly degarelix for injection) or monthly leuprolide in prostate cancer patients during the first year of treatment. Prostate cancer patients who received FIRMAGON 240/80 mg/month had a recurrence rate of 7.7% during the first year of treatment compared with 12.9% of patients treated with leuprolide 7.5 mg/month (p=0.05). Patients being treated with FIRMAGON also had longer time to recurrence compared with those on leuprolide (p=0.04). Results of the PSA analysis were presented in a poster at the 10th Annual Meeting of the Society of Urologic Oncology, held in conjunction with the World Urological Oncology Federation, on December 3 in Bethesda, MD.

About the Study

In the Phase III multicenter, randomized, open-label trial comparing degarelix with leuprolide, prostate cancer patients (n=610) were randomized to a starting dose of degarelix 240 mg for one month, followed by monthly maintenance doses of 80 mg (n=207) or 160 mg (n=202), or leuprolide 7.5 mg/month (n=201). Results showed that degarelix is as effective as leuprolide in reducing and sustaining castrate levels of testosterone.1,2 Suppression of testosterone to castrate levels occurred significantly faster in patients receiving degarelix than in those receiving leuprolide.1,2 The study also showed that degarelix achieves faster suppression of luteinizing hormone and follicle-stimulating hormone.1,2 PSA recurrence was defined as two consecutive increases in PSA of 50% compared with nadir and ≥5 ng/mL on two consecutive measurements at least two weeks apart. PSA progression-free survival was analyzed using the Kaplan-Meier method and “time to event” was defined as the number of days from first dosing to the first occurrence of PSA recurrence or death. PSA recurrences were analyzed by baseline PSA level.

PSA recurrence was 12.9% for leuprolide 7.5 mg/month patients compared to 7.7% with the approved degarelix 240/80 regimen. The probability of completing the study without experiencing PSA recurrence by day 364 was 91.1% (95% CI: 85.9-94.5) for degarelix and 85.9% (95% CI: 79.9-90.2) for leuprolide 7.5 mg/mo. The probability of completing the study without dying by day 364 was 97.4% (95% CI: 93.8-98.9) for degarelix versus 95.1% (95% CI: 90.7-97.4) for leuprolide 7.5 mg/mo. In patients with baseline PSA >20 ng/mL, risk of PSA recurrence was lower for patients receiving degarelix compared with leuprolide (p=0.04). The risk of PSA recurrence was comparable in patients with baseline PSA >50 ng/mL (p=0.10). At Day 3 of treatment, the degarelix group achieved a 90 percent decrease in median testosterone levels compared with the leuprolide group, which experienced a 65 percent increase in median testosterone levels. Degarelix was as effective as leuprolide in suppressing testosterone levels from Day 28 to the end of the study (Day 364), with 97.2% of the degarelix patients maintaining medical castrate levels compared with 96.4% for leuprolide.

About FIRMAGON

FIRMAGON is an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer. As a receptor antagonist, FIRMAGON reversibly binds to the GnRH receptors in the pituitary gland, immediately suppressing the secretion of the luteinizing hormone (LH), follicle-stimulating hormone (FSH), and subsequently, testosterone levels.1-4 FIRMAGON also reduces levels of prostate-specific antigen (PSA). Unlike luteinizing hormone-releasing hormone (LHRH) agonists, such as leuprolide, an established treatment for prostate cancer, FIRMAGON does not induce an initial testosterone surge. FIRMAGON is administered monthly by subcutaneous injection. The starting dose is 240 mg, followed by monthly maintenance doses of 80 mg. FIRMAGON is available for order through traditional and specialty pharmacy distributors. The average monthly cost of one year of FIRMAGON treatment is comparable to other hormone treatments for prostate cancer. The most commonly observed adverse reactions during FIRMAGON therapy included injection site reactions (e.g. pain, erythema, swelling or induration) and other androgen deprivation therapy (ADT) associated side effects including hot flashes, increased weight and fatigue. Ninety-nine percent of these observed adverse reactions were Grade 1 or 2 (mild to moderate). Specifically relating to the injection site adverse reactions, most were transient, of mild to moderate intensity, occurred primarily with the starting dose and led to few discontinuations (<1%). Grade 3 (severe) injection site reactions occurred in two percent or less of patients receiving FIRMAGON.

FIRMAGON is contraindicated in patients with known hypersensitivity to degarelix or to any of the product components. FIRMAGON is not indicated in women or pediatric patients. Long-term ADT prolongs the QT interval. Physicians should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in patients taking Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmic medications.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of infertility, urology, and orthopaedic products in the U.S. market. They include: BRAVELLE^® (urofollitropin for injection, purified), MENOPUR^® and REPRONEX^® (menotropins for injection, USP), NOVAREL^® (chorionic gonadotropin for injection, USP), ENDOMETRIN^® (progesterone) Vaginal Insert, 100 mg, FIRMAGON^® (degarelix for injection), PROSED^® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), DESMOPRESSIN, and EUFLEXXA^® (1% sodium hyaluronate). Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For more information, call 1-888- FERRING (1-888-337-7464) or visit www.FerringUSA.com.

*Lupron Depot^® (leuprolide acetate for depot suspension) is a registered trademark of TAP Pharmaceuticals Inc.

RESEARCH COMPARES MENOPUR® WITH rFSH IN GNRH ANTAGONIST IVF CYCLES

Fri, 29 Jan 2010 21:28:35 +0000

Ferring Pharmaceuticals Presents Study Results at American Society for Reproductive Medicine Annual Meeting

ATLANTA – October 20, 2009 – Ferring Pharmaceuticals presented an interim study analysis indicating that MENOPUR^® (menotropins for injection, USP) is effective in in vitro fertilization (IVF) cycles using a gonadotropin-releasing hormone (GnRH) antagonist. The results were presented in a poster at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Atlanta, October 17-21, 2009.

MENOPUR^® vs. rFSH in GnRH Antagonist Cycles Interim Study Analysis

In an interim analysis of a multicenter, randomized, open-label exploratory study of IVF cycles using a GnRH antagonist, patients were randomized prior to stimulation with either MENOPUR^® or recombinant follicle stimulating hormone (rFSH), and luteal support with either ENDOMETRIN^® (progesterone) Vaginal Insert 100 mg or progesterone-in-oil (PIO). The overall continuing pregnancy rate was 43.1 percent (n=143), with pregnancy rates of 46.7 percent for the MENOPUR^® group (n=68) and 40.0 percent for the rFSH group (n=75). Results of the analysis indicate that MENOPUR^® is effective in IVF cycles using a GnRH antagonist, and the efficacy of ENDOMETRIN^® is equivalent to that of PIO for luteal support.

“We are very encouraged by these interim results,” said Ed Trott, vice president, medical affairs. “We anticipate that the final results of the study will add to the growing body of evidence suggesting that hMG offers better embryo quality and higher implantation and live birth rates when compared to using rFSH alone.”

About MENOPUR

MENOPUR^® administered subcutaneously is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an ART program.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe MENOPUR^®. MENOPUR^®, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (overall incidence 3.8%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. MENOPUR^® is contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; sex hormone dependent tumors of the reproductive tract and accessory organs; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to menotropins or MENOPUR^®. MENOPUR^® is not indicated in women who are pregnant. There are limited human data on the effects of menotropins when administered during pregnancy.

About ENDOMETRIN

ENDOMETRIN^® administered as a progesterone vaginal insert is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment for infertile women.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment should prescribe ENDOMETRIN^®. In clinical trials (n=808), adverse reactions that occurred at a rate greater than or equal to 2 percent included: uterine spasm (3% to 4%) and vaginal bleeding (3%). Vaginal irritation, itching, burning or discomfort, urticaria, and peripheral edema were reported at an incidence of less than 2 percent. ENDOMETRIN^® is expected to have adverse reactions similar to other drugs containing progesterone (breast tenderness, bloating, mood swings, irritability, and drowsiness). ENDOMETRIN^® is contraindicated in women who have or have had previous allergic reactions to progesterone or any of the ingredients in ENDOMETRIN^® ; a known missed abortion or ectopic pregnancy; liver disease; known or suspected breast cancer; active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments of any manufacturer in the U.S. The Company markets MENOPUR^®, BRAVELLE^® (urofollitropin for injection, purified), REPRONEX^® (menotropins for injection, USP), NOVAREL^® (chorionic gonadotropin for injection, USP) and ENDOMETRIN^® in the U.S. to infertility specialists and their patients. Ferring also offers the Q∙CAP™, the first and only needle-free reconstitution device, for use with its fertility treatments. Ferring’s line of urology products includes FIRMAGON^® (degarelix for injection) and PROSED^® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate). Ferring’s orthopaedic product includes EUFLEXXA™ (1% sodium hyaluronic acid). Other products include ACTHREL^® (corticorelin ovine triflutate for injection) and DESMOPRESSIN. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology, infertility and orthopaedics. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

Please visit www.ferringfertility.com for Full Prescribing Information for MENOPUR^® and ENDOMETRIN^®.

RECENTLY PUBLISHED STUDY DEMONSTRATES PHARMACOKINETIC ADVANTAGES OF ENDOMETRIN® OVER CRINONE® FOR PROGESTERONE SUPPLEMENTATION

Tue, 01 Sep 2009 18:39:26 +0000

Study Published Online in Fertility & Sterility

PARSIPPANY, NJ – August 31, 2009 – ENDOMETRIN^® (progesterone) Vaginal Inserts, 100 mg showed clear advantages over Crinone* (progesterone gel) for progesterone supplementation, according to the results of a new pharmacokinetic (PK) study. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo and to support early pregnancy.

ENDOMETRIN^® rapidly reached higher progesterone serum concentrations, produced greater systemic exposure (AUC 0-24), achieved steady state more rapidly, and cleared more rapidly after termination of therapy than Crinone. The study results were published online in Fertility & Sterility, July 15, 2009.

“We are extremely pleased to bring the fertility community a progesterone supplement that dissolves, achieves steady state and clears faster than gel while providing convenience and comfort to patients,” said Ed Trott, vice president, medical affairs. “The study results support the benefits provided by ENDOMETRIN^®’s unique mechanism of action, or as we like to say, Dissolves. Delivers. Done.”

About the Study

The randomized, open-label, parallel design PK study tested three groups of six healthy subjects, randomized to take ENDOMETRIN^® two times a day or three times a day or Crinone 8% gel daily. Testing was done for a single day and for multiple days. On the single day of dosing, mean Cmax was 17.0 ng/mL in the two times a day group, 19.8 ng/mL in the three times a day group, and 6.8 ng/mL in the gel group. The 24-hour systemic exposure AUC (0-24) was 217 ng·h/mL in the two times a day insert group, 284 ng·h/mL in the three times a day group, and 81ng·h/mL in the gel group.

During the multiple days of dosing, ENDOMETRIN^® treatments reached steady state within the first two days (24-32 hours), much more rapidly than the gel, which had not reached steady state by 5 days. At 5 days, the ENDOMETRIN^® treatments produced sustained progesterone concentrations exceeding 10 ng/mL across 24 hours. The results suggest that ENDOMETRIN^® can reach a targeted concentration range in a substantially shorter time than Crinone. Both ENDOMETRIN^® groups demonstrated a higher Cmax than the Crinone group, with greater systemic exposures. Both the vaginal inserts and the gel were generally safe and well tolerated, and all adverse events were mild.

About ENDOMETRIN

Important Safety Information

About Ferring Pharmaceuticals

Ferring’s line of urology products includes FIRMAGON^® (degarelix for injection) and PROSED^® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate). Ferring’s orthopaedic product includes EUFLEXXA™ (1% sodium hyaluronic acid). Other products include ACTHREL^® (corticorelin ovine triflutate for injection) and DESMOPRESSIN. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology, infertility and orthopaedics. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

*Crinone is a registered trademark of Columbia Laboratories.

Please visit www.ferringfertility.com for Full Prescribing Information for ENDOMETRIN^®.

FERRING PHARMACEUTICALS ANNOUNCES TRADE NAME FIRMAGON® (degarelix for injection) FOR ADVANCED PROSTATE CANCER TREATMENT

Tue, 04 Aug 2009 13:30:10 +0000

PARSIPPANY, NJ – August 4, 2009 – Ferring Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved the trade name FIRMAGON^® (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix. FIRMAGON is a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer. Since initial market introduction under the generic name degarelix, FIRMAGON has been used by more than 3,000 patients to fight their prostate cancer.

“This treatment was in development by Ferring Pharmaceuticals in the U.S. and Europe for more than a decade,” said Wayne Anderson, President and CEO of Ferring Pharmaceuticals Inc., USA. “We launched degarelix prior to receiving approval for its brand name in order to bring the medical community an effective alternative in the treatment of advanced prostate cancer without delay. We plan to continue our research in the area of urology and we expect to introduce additional treatment advances in the future.”

FIRMAGON provides fast, long-term suppression of testosterone, a hormone that stimulates prostate cancer growth.^1-3 Phase III pivotal studies showed that FIRMAGON is as effective as leuprolide (Lupron Depot^®)* in reducing and sustaining castrate levels of testosterone.^1,2 Suppression of testosterone to castrate levels occurred significantly faster in patients receiving FIRMAGON than in those receiving leuprolide.^1,2 At Day 3 of treatment, the FIRMAGON group achieved a 90 percent decrease in median testosterone levels compared with the leuprolide group, which experienced a 65 percent increase in median testosterone levels, a statistically significant result. FIRMAGON was as effective as leuprolide in suppressing testosterone levels from Day 28 to the end of the study (Day 364), with 97.2 percent of the FIRMAGON patients maintaining medical castrate levels compared with 96.4 percent for leuprolide.

In addition, prostate-specific antigen (PSA) levels were lowered by 64 percent two weeks after administration of FIRMAGON, 85 percent after one month, 95 percent after three months, and remained suppressed throughout the one year of treatment.^1,2 These PSA results should be interpreted with caution because of the heterogeneity of the patient population studied. No evidence has shown that the rapidity of PSA decline is related to a clinical benefit. FIRMAGON is the exact same product as degarelix and carries the same National Drug Code (NDC). FIRMAGON is being reimbursed by all Medicare Administrative Carriers and virtually all commercial insurers. A free reimbursement assistance hotline for FIRMAGON is available at 1-877-971-3778 and has already assisted hundreds of patients and physician offices. Centers for Medicare & Medicaid Services (CMS) reimbursement rates are on their Web site and can be accessed at http://tinyurl.com/kl79hr. For complete prescribing information, visit www.FIRMAGON.com.

About FIRMAGON

The most commonly observed adverse reactions during FIRMAGON therapy included injection site reactions (e.g. pain, erythema, swelling or induration), hot flashes, increased weight, fatigue, and increases in serum levels of transaminases and gammaglutamyltransferase (GGT). Ninety-nine percent of these observed adverse reactions were Grade 1 or 2 (mild to moderate). Specifically relating to the injection site adverse reactions, most were transient, of mild to moderate intensity, occurred primarily with the starting dose and led to few discontinuations (<1%). Grade 3 (severe) injection site reactions occurred in two percent or less of patients receiving FIRMAGON.

FIRMAGON is contraindicated in patients with known hypersensitivity to degarelix or to any of the product components. FIRMAGON is not indicated in women or pediatric patients. Long-term androgen deprivation therapy prolongs the QT interval. Physicians should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in patients taking Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmic medications.

About Ferring Pharmaceuticals Inc.

*Lupron Depot^® (leuprolide acetate for depot suspension) is a registered trademark of TAP Pharmaceuticals Inc.

FERRING PHARMACEUTICALS UNVEILS SIX-MONTH EFFICACY DATA FOR EUFLEXXA® FOR THE TREATMENT OF OSTEOARTHRITIS KNEE PAIN

Thu, 14 May 2009 20:34:16 +0000

Results Show Superior Decrease in Pain Scores Compared to Saline

PARSIPPANY, NJ – May 13, 2009 – Ferring Pharmaceuticals recently presented the results of a six-month safety and efficacy study demonstrating that EUFLEXXA^® (1% sodium hyaluronate) was effective at decreasing the pain of knee osteoarthritis (OA) at 26 weeks. The study showed that EUFLEXXA ^® is superior to saline in decreasing pain at 26 weeks in patients with OA of the knee.¹ The study results were presented by Dr. Roy D. Altman in a poster at the Annual Meeting of the American Academy of Orthopedic Surgeons on February 23, 2009. EUFLEXXA^® is a three-injection treatment regimen indicated for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. The goal of hyaluronic acid (HA) therapy is to reduce pain and improve physical function by replenishing the HA in human synovial fluid (fluid in joints). In OA, this fluid becomes thinner, leading to a decrease in elasticity and viscosity.

About the Study

The multicenter, 26-week, randomized, double-blind trial compared EUFLEXXA^® and intra-articular buffered saline (IA-SA) for level of pain following a 50-Foot Walk Test, measured by 100 mm visual analog scale (VAS). The 586 patients with chronic idiopathic knee OA were randomized to treatment with either product in a 1:1 ratio. Each patient received one weekly injection for 3 weeks with 9 follow-up visits over 26 weeks after the first injection. The EUFLEXXA^® group showed an advantage over saline in pain reduction, with a larger mean decrease from baseline in pain scores: -25.7 (28.9) mm versus -18.5(32.5) mm respectively, with a least squares means of -6.6 mm (P=0.002). At 26 weeks, 145 (58%) of EUFLEXXA^® subjects reported a ≥20-mm improvement in pain based on the VAS scoring, compared with 120 (46%) in the other group (P=0.006). The percentage of Osteoarthritis Research Society International (OARSI) responders for the EUFLEXXA^® group was also significantly greater than that in the other group (67% versus 59% (P=0.047). A subject is considered a responder if there is a high improvement in pain or function, or improvement in at least two of the following three categories: pain ≥20% and absolute change ≥10 mm, function ≥20% and absolute change ≥10 mm, and/or patient global assessment ≥20% and absolute change.

About EUFLEXXA^®

EUFLEXXA^® (1% sodium hyaluronate) is the first non-avian derived* hyaluronic acid (HA) approved in the U.S. for treatment of knee pain due to osteoarthritis (OA). EUFLEXXA^® is indicated for patients who have failed to get adequate pain relief either from simple pain medications, such as acetaminophen, or from exercise and/or physical therapy. The process used to manufacture EUFLEXXA^® results in highly-purified HA with properties similar to the HA in healthy human synovial fluid.^2-4 EUFLEXXA^® received approval from the U.S. Food and Drug Administration (FDA) on December 3, 2004, and became available to the public on November 8, 2005. For more information, visit www.EUFLEXXA.com.

EUFLEXXA^® should not be used in people who have had any previous allergic reaction to hyaluronate preparations or who have knee joint infections or skin diseases in the area of the injection site. Common adverse events reported were arthralgia (joint pain) and back pain. Temporary knee pain and swelling may occur after injection. Strict aseptic technique must be followed to avoid joint infection.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For complete prescribing information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

*Derived through bacterial fermentation

FERRING PHARMACEUTICALS LAUNCHES PHASE IIIB TRIAL OF DEGARELIX AS INTERMITTENT THERAPY

Thu, 14 May 2009 20:47:56 +0000

Trial Will Build on Pivotal Phase III Study for the Treatment of Advanced Prostate Cancer

PARSIPPANY, NJ – April 27, 2009 – Ferring Pharmaceuticals announced today the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer. The announcement was made at the 2009 American Urological Association Annual Meeting in Chicago, IL. The Phase IIIB trial will investigate the use of degarelix for intermittent androgen deprivation therapy (IADT) in patients with advanced prostate cancer who have rising serum PSA levels after previous curative therapies. The study will compare IADT to continuous androgen deprivation therapy (ADT) for 14 months with either leuprolide or degarelix. The trial evaluates whether IADT minimizes the negative effects of ADT and maximizes quality of life, while maintaining tumor response as measured by PSA suppression. “Intermittent androgen deprivation therapy is a commonly employed treatment for men with biochemical failure, however it needs to be evaluated in a randomized clinical trial,” says Dr. E. David Crawford, Head Urologic Oncology, University of Colorado, Denver and a trial investigator. “There is potential value in combining the rapid, sustained suppression of testosterone that degarelix offers in this treatment. IADT appears to improve patient quality of life and that will also be evaluated.”

Physicians interested in serving as trial investigators should call 1-973-796-1600 to speak with Ferring Pharmaceuticals’ Medical Information office.

Degarelix Phase III Trials

Phase III pivotal studies showed that degarelix is as effective as leuprolide (Lupron Depot^®)* in reducing and sustaining castrate levels of testosterone.1,2 Suppression of testosterone to castrate levels occurred significantly faster in patients receiving degarelix than in those receiving leuprolide.^1,2 At Day 3 of treatment, the degarelix group achieved a 90 percent decrease in median testosterone levels compared with the leuprolide group, which experienced a 65 percent increase in median testosterone levels, a statistically significant result . Degarelix was as effective as leuprolide in suppressing testosterone levels from Day 28 to the end of the study (Day 364), with 97.2 percent of the degarelix patients maintaining medical castrate levels compared with 96.4 percent for leuprolide.

In addition, prostate-specific antigen (PSA) levels were lowered by 64 percent two weeks after administration of degarelix, 85 percent after one month, 95 percent after three months, and remained suppressed throughout the one year of treatment.^1,2 These PSA results should be interpreted with caution because of the heterogeneity of the patient population studied. No evidence has shown that the rapidity of PSA decline is related to a clinical benefit.

About Degarelix

Degarelix also reduces levels of prostate-specific antigen (PSA). Unlike luteinizing hormonereleasing hormone (LHRH) agonists, such as leuprolide, an established treatment for prostate cancer, degarelix does not induce an initial testosterone surge. Degarelix is administered monthly by subcutaneous injection. The starting dose is 240 mg, followed by monthly maintenance doses of 80 mg. Degarelix is available for order through traditional and specialty pharmacy distributors. The average monthly cost of one year of degarelix treatment is comparable to other hormone treatments for prostate cancer.

The most commonly observed adverse reactions during degarelix therapy included injection site reactions (e.g. pain, erythema, swelling or induration), hot flashes, increased weight, fatigue, and increases in serum levels of transaminases and gammaglutamyltransferase (GGT). Ninety-nine percent of these observed adverse reactions were Grade 1 or 2 (mild to moderate). Specifically relating to the injection site adverse reactions, most were transient, of mild to moderate intensity, occurred primarily with the starting dose and led to few discontinuations (<1%). Grade 3 (severe) injection site reactions occurred in two percent or less of patients receiving degarelix.

Degarelix is contraindicated in patients with known hypersensitivity to degarelix or to any of the product components. Degarelix is not indicated in women or pediatric patients. Longterm androgen deprivation therapy prolongs the QT interval. Physicians should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in patients taking Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmic medications.

About Prostate Cancer

Prostate cancer is the most common cancer, excluding skin cancers, and the second leading cause of cancer death in American men. About one man in six will be diagnosed with prostate cancer during his lifetime, and one in 35 will die of this disease.⁴ Prostate cancer develops from cells in the prostate gland that begin to grow out of control. In most cases, prostate cancer grows slowly and can remain undetected throughout a man’s life, although it can grow and spread quickly.⁵ The four types of standard treatment are: watchful waiting, surgery, radiation therapy, and hormone therapy, also called androgen deprivation therapy (ADT).

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility. For complete prescribing information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

*Lupron Depot^® (leuprolide acetate for depot suspension) is a registered trademark of TAP Pharmaceuticals Inc.

FERRING PHARMACEUTICALS AND RESOLVE: THE NATIONAL INFERTILITY ASSOCIATION JOIN TOGETHER TO LAUNCH NURSE LIAISON PROGRAM

Mon, 04 May 2009 19:08:47 +0000

Program to Launch During RESOLVE’s National Infertility Awareness Week^®, April 25 - May 2 Across the Country

PARSIPPANY, NJ – April 27, 2009 – Ferring Pharmaceuticals, which offers the broadest portfolio of fertility treatments in the U.S., has partnered with leading patient advocate organization, RESOLVE: The National Infertility Association, to launch the RESOLVE Nurse Liaison Program during National Infertility Awareness Week^® (NIAW), April 25-May 2. The program was developed to create a network of nurses from every Society for Assisted Reproductive Technology (SART) member infertility center in the United States to serve as RESOLVE ambassadors in their medical practice. Since nurses play a crucial role in the patient care process, the program was designed to arm them with relevant information about treatment options and valuable educational materials for infertility patients.

Nurses who enroll in the RESOLVE Nurse Liaison Program will receive e-communication on a regular basis with up-to-date patient education materials and other available resources. In addition, RESOLVE will periodically ask for feedback from nurses on the current state of patient education in infertility and gaps that they see in patient’s knowledge. As a member of this valuable program, nurses will be prominently featured on RESOLVE’s Web site and have the opportunity to contribute articles and speak at RESOLVE events.

“RESOLVE is proud to collaborate with Ferring Pharmaceuticals especially during National Infertility Awareness Week^®. Our goal is to spread information about infertility and its treatments to those fighting the disease of infertility,” said Barbara Collura, RESOLVE’s executive director. “We are thrilled to be partnering with a leader in the field of infertility who can help RESOLVE provide vital information to the nurses who are on the front lines of the patient care journey.”

“Ferring is pleased to be working with RESOLVE to give nurses the resources they need to enhance the patient care journey,” said Olivier Delannoy, vice president, Infertility Business Unit at Ferring. “As a leader in providing patients with access to affordable and user-friendly treatment options, Ferring remains committed to supporting the reproductive community with the tools they need to help simplify the patient treatment process.”

Nurses who are interested in becoming a member of the RESOLVE Nurse Liaison Program can visit www.resolve.org/nurseprogram. Upon receipt of the registration form, RESOLVE will send a program welcome packet that outlines the details of the program.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments in the U.S. The Company markets MENOPUR, BRAVELLE, REPRONEX^® (menotropins for injection, USP), NOVAREL^® (chorionic gonadotropin for injection, USP) and ENDOMETRIN^® (progesterone) Vaginal Insert in the U.S. to infertility specialists and their patients. Ferring also offers the Q∙CAP™, the first and only needle-free reconstitution device, for use with its fertility treatments.

Ferring’s line of orthopaedic and urology products includes EUFLEXXA^® (1% sodium hyaluronic acid) and PROSED^® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate). Other products include: ACTHREL^® (corticorelin ovine triflutate for injection), DESMOPRESSIN and DEGARELIX for injection.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology, infertility and orthopaedics. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

About RESOLVE: The National Infertility Association

Founded in 1974, RESOLVE: The National Infertility Association, headquartered in McLean, VA, is the oldest and largest consumer-based, nonprofit group that provides education, advocacy and compassionate support for those struggling with infertility in the United States. Each year, RESOLVE and its nationwide network of affiliates handle more than 1.5 million contacts from people seeking information and help. For more information, visit the RESOLVE website at www.resolve.org.

NEW APPROACH TO PROGESTERONE SUPPLEMENTATION IN ART REVEALED IN RECENTLY PUBLISHED WHITE PAPER

Thu, 23 Apr 2009 15:00:01 +0000

Expert Panel: Vaginal Progesterone Preferred for Luteal Support in ART

PARSIPPANY, NJ – April 13, 2009 – Ferring Pharmaceuticals, a leader in the infertility market with the broadest portfolio of treatments in the U.S., today released a white paper titled, Recommendations on the Use of Vaginal Progesterone for Luteal-Phase Support in Assisted Reproductive Technology (ART) Procedures. The paper was drafted after an expert panel of renowned reproductive endocrinologists from the U.S. and Europe convened in New York City on December 19, 2008 to discuss the utility of vaginal progesterone for luteal phase support during ART. After critical review and discussion of personal clinical data and experience with progesterone in ART, the experts concluded that vaginal progesterone should be the standard-of-care when considering progesterone formulations in ART and that vaginal progesterone provides improved patient comfort over intramuscular (IM) progesterone without compromising pregnancy rates.

The objective of the meeting was to reach a consensus based on physician experience regarding which progesterone formulation is preferred from a clinical and patient-acceptance perspective. The vaginal progesterone formulations that were compared with intramuscular progesterone included: Crinone^®, Prometrium^® oral tablets, compounded vaginal suppositories and capsules, and ENDOMETRIN^® (progesterone) Vaginal Insert 100 mg – the most recent progesterone supplement to be approved by the U.S. Food and Drug Administration (FDA).

“The clear take-away from this expert roundtable meeting is that both physicians and patients prefer the comfort and convenience of vaginal progesterone formulations,” said Alan Penzias, MD, reproductive endocrinologist and surgical director at Boston IVF. “Before vaginal progesterone formulations were introduced, IM progesterone was the standard-of-care for luteal support, however, recently introduced vaginal formulations such as ENDOMETRIN have demonstrated equivalent pregnancy rates to IM. This allows us to confidently prescribe a progesterone supplement that is not only effective, but can also enhance a patient’s quality of life.”

One of the most recent studies published that supports equivalent pregnancy rates between vaginal progesterone and IM progesterone was presented by Angeline Beltsos, MD, medical director of Fertility Centers of Illinois in Chicago and one of the expert panelists, at the 2008 American Society for Reproductive Medicine (ASRM) meeting. The analysis evaluated serum progesterone levels and pregnancy outcomes with ENDOMETRIN vaginal inserts (n=568) compared with IM progesterone (n=751). Results from the study showed equivalent pregnancy rates with vaginal progesterone versus IM progesterone.1

Key Findings from the Roundtable

Luteal phase support should be initiated on the evening of or the day after oocyte retrieval. It is critical for the first two weeks and should continue for six to eight weeks after a positive pregnancy test is obtained.
Medical literature strongly supports that vaginal progesterone is as efficacious as IM progesterone, in terms of pregnancy rates.
Vaginal progesterone likely provides improved patient comfort than IM progesterone, without sacrificing efficacy.
Patients should be reassured that minimal bleeding with vaginal progesterone does not affect pregnancy outcomes. Bleeding is the result of not becoming pregnant and not necessarily the cause.
The measurement of serum progesterone has low clinical utility when using progesterone in luteal support.
Pharmaceutical grade FDA-approved vaginal progesterone products are preferred over pharmacy-compounded products.
The use of vaginal progesterone should be emphasized in the training of future RE’s and IVF nurses in the area of ART.

In the overall findings, the panel recommended that vaginal progesterone should be the standard-of-care when considering progesterone formulations in ART.

About ENDOMETRIN

Important Safety Information

Only physicians thoroughly familiar with infertility treatment should prescribe ENDOMETRIN^®. In clinical trials (n=808), adverse reactions that occurred at a rate greater than or equal to 2% included: uterine spasm (3% to 4%) and vaginal bleeding (3%). Vaginal irritation, itching, burning or discomfort, urticaria, and peripheral edema were reported at an incidence of less than 2%. ENDOMETRIN^® is expected to have adverse reactions similar to other drugs containing progesterone (breast tenderness, bloating, mood swings, irritability, and drowsiness). ENDOMETRIN^® is contraindicated in women who have or have had previous allergic reactions to progesterone or any of the ingredients in ENDOMETRIN^®; a known missed abortion or ectopic pregnancy; liver disease; known or suspected breast cancer; active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments in the U.S. The Company markets MENOPUR, BRAVELLE, REPRONEX^® (menotropins for injection, USP), NOVAREL^® (chorionic gonadotropin for injection, USP) and ENDOMETRIN^® (progesterone) Vaginal Insert in the U.S. to infertility specialists and their patients. Ferring also offers the Q∙CAP™, the first and only needle-free reconstitution device, for use with its fertility treatments.

Please visit www.ferringfertility.com for Full Prescribing Information for ENDOMETRIN.

Reference: 1. Martin-Johnston M, Beltsos A, Robertson A, et al. Luteal phase support with Endometrin^® vs. progesterone in oil in in vitro fertilization cycles. Fertil Steril. 2008;90 (Suppl 1): S459.

Crinone is a registered trademark of Columbia Laboratories, Inc.
Prometrium is a registered trademark of Solvay Pharmaceuticals

THRIVING FERRING TO OPEN NEW SITE -
PHARMACEUTICAL IS EXPANDING LOCALLY
San Diego Union-Tribune
February 10, 2009

Tue, 24 Mar 2009 20:51:18 +0000

FERRING SUPPORTS A ROUNDTABLE DISCUSSION ABOUT COLLABORATIVE INFERTILITY CARE BETWEEN REPRODUCTIVE ENDOCRINOLOGISTS AND OBGYNS

Tue, 24 Mar 2009 20:50:55 +0000

FERRING PHARMACEUTICALS ANNOUNCES IMMEDIATE AVAILABILITY OF DEGARELIX FOR THE TREATMENT OF ADVANCED PROSTATE CANCER

Wed, 04 Mar 2009 15:35:11 +0000

New Drug Provides Rapid and Sustained Suppression of Testosterone

PARSIPPANY, NJ – March 4, 2009 – Ferring Pharmaceuticals, USA today announced the U.S. commercial availability of degarelix for injection (trade name pending), a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer. Degarelix is available for order through traditional and specialty pharmacy distributors.

Degarelix provides fast, long-term suppression of testosterone, a hormone that stimulates prostate cancer growth.^1-3 Clinical trials demonstrated that degarelix is effective in quickly reducing and sustaining castrate levels of testosterone.^2,3 Degarelix works differently than a luteinizing hormone-releasing hormone (LHRH) agonist by binding immediately and reversibly to GnRH receptors in the pituitary gland, quickly reducing the release of gonadotropins and consequently testosterone. In the Phase III study vs. leuprolide, the degarelix group achieved a 90 percent decrease in median testosterone levels at Day 3 of treatment, compared with the leuprolide group, which experienced a 65 percent increase in median testosterone levels. By Day 3, 96 percent of degarelix patients achieved castrate levels of testosterone, compared with zero percent receiving leuprolide. In addition, degarelix was as effective as leuprolide in suppressing testosterone levels from Day 28 to the end of the study (Day 364), with 97.2 percent of the degarelix patients maintaining medical castrate levels compared with 96.4 percent for leuprolide.

Study findings also showed that prostate specific antigen (PSA) levels were lowered by 64 percent two weeks after administration of degarelix, 85 percent after one month, 95 percent after three months, and remained suppressed throughout the one year of treatment.^1,2 These PSA results should be interpreted with caution because of the heterogeneity of the patient population studied. No evidence has shown that the rapidity of PSA decline is related to a clinical benefit.

“Degarelix, the lead product in our urology portfolio, demonstrated both a rapid onset of action and a profound long-term suppression of testosterone,” said Wayne Anderson, President and CEO Ferring Pharmaceuticals Inc., USA. “Now, advanced prostate cancer can be treated with a direct-acting GnRH receptor antagonist inducing rapid reduction of testosterone and sustaining those levels over time, meeting the goals of systemic therapy. We are excited to provide this effective new treatment option for men fighting advanced prostate cancer.”

Approved by the FDA on December 24, 2008, degarelix represents Ferring Pharmaceuticals’ first global launch and the second urology product launch for Ferring Pharmaceuticals, USA. The European Commission granted marketing authorization for degarelix on February 19, 2009. Degarelix is awaiting approval in other key global markets.

Phase III Study Results

The 12-month, randomized, open-label, parallel-group Phase III study evaluated the efficacy and safety of degarelix compared with leuprolide administered monthly over one year of
prostate cancer treatment. Patients with histologically confirmed prostate cancer were randomized to either degarelix or leuprolide: a degarelix subcutaneous (under the skin) injection
of 240 mg for one month with monthly maintenance doses of 80 mg (n=207) or monthly intramuscular (into the muscle) injections of leuprolide depot 7.5 mg (n=201).

The primary endpoint was testosterone suppression to ≤50 ng/dL during monthly measurements from Day 28 to Day 364. Degarelix was at least as effective as leuprolide in achieving and maintaining castrate levels of testosterone.

	N	Patients with treatment response	% (95% CI)
Degarelix 240/80 mg	207	202	97.2
Leuprolide 7.5 mg	201	194	96.4

Suppression of testosterone levels to ≤50 ng/dL occurred significantly faster in patients receiving degarelix than in those receiving leuprolide. At Day 3 of treatment, the degarelix group achieved a 90 percent decrease in median testosterone levels, compared to the leuprolide group which experienced a 65 percent increase in median testosterone levels.

The most commonly observed adverse reactions during degarelix therapy included injection site reactions (e.g. pain, erythema, swelling or induration), hot flashes, increased weight, fatigue, and increases in serum levels of transaminases and gamma-glutamyltransferase (GGT). Ninety-nine percent of these observed adverse reactions were Grade 1 or 2 (mild to moderate). Specifically relating to the injection site adverse reactions, most were transient, of mild to moderate intensity, occurred primarily with the starting dose and led to few discontinuations (<1%). Grade 3 (severe) injection site reactions occurred in two percent or less of patients receiving degarelix.

Degarelix is contraindicated in patients with known hypersensitivity to degarelix or to any of the product components. Degarelix is not indicated in women or pediatric patients. Long-term androgen deprivation therapy prolongs the QT interval. Physicians should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in patients taking Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmic medications.

About Degarelix

Degarelix is an injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer. As a receptor antagonist, degarelix reversibly binds to the GnRH receptors in the pituitary gland, immediately suppressing the secretion of the luteinizing hormone (LH), follicle-stimulating hormone (FSH), and subsequently, testosterone levels.⁴ Degarelix also reduces levels of prostate-specific antigen (PSA). Unlike LHRH agonists, such as leuprolide, an established treatment for prostate cancer, degarelix does not induce an initial testosterone surge. Degarelix is administered monthly by subcutaneous injection. The starting dose is 240 mg, followed by monthly maintenance doses of 80 mg. Degarelix is available for order through traditional and specialty pharmacy distributors. The average monthly cost of one year of degarelix treatment is comparable to other hormone treatments for prostate cancer.

About Prostate Cancer

Prostate cancer is the most common cancer, excluding skin cancers, and the second leading cause of cancer death in American men. About one man in six will be diagnosed with prostate cancer during his lifetime, and one in 35 will die of this disease.⁵ Prostate cancer develops from cells in the prostate gland that begin to grow out of control. In most cases, prostate cancer grows slowly and can remain undetected throughout a man’s life, although it can grow and spread quickly.⁶ The four types of standard treatment are: watchful waiting, surgery, radiation therapy, and hormone therapy, also called androgen deprivation therapy (ADT).

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of urology,
orthopaedic and infertility products in the U.S. market. They include: EUFLEXXA^{^®} (1% sodium hyaluronic acid), BRAVELLE^{^®} (urofollitropin for injection, purified), MENOPUR^{^®} and
REPRONEX^{^®} (menotropins for injection, USP), Novarel^{^®} (chorionic gonadotropin for injection, USP), ENDOMETRIN^{^®} (progesterone) Vaginal Insert, ACTHREL^{^®} (corticorelin ovine
triflutate for injection), PROSED^{^®} DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), Degarelix for injection, and DESMOPRESSIN.

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology and infertility. For complete prescribing information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

FERRING PHARMACEUTICALS ANNOUNCES THREE STUDENT WINNERS OF TERRY MCMORROW SCHOLARSHIPS

Tue, 24 Mar 2009 20:51:42 +0000

Parsippany, NJ – February 17, 2009 – Ferring Pharmaceuticals has announced the three local student winners of its Terry McMorrow Memorial Scholarships. The scholarships are based on achievement, leadership, honors, participation in school and community activities, and educational and career goals.

“We are very pleased to present scholarships to these promising students who demonstrate the same ideals that we recognize and reward in Ferring employees,” said Wayne Anderson, president and CEO. “Drive, dedication and pursuit of high achievement are part of our corporate culture, and the traits exemplified by our former revered employee, Terry McMorrow. We hope these scholarships will give them a good start in the pursuit of their career goals.”

A $10,000 scholarship for the most promising high school senior in Parsippany was awarded to Maegan Samuel, a student at Parsippany High School. Maegan will be attending Howard University in the fall in honor of her father, the late Dr. David M. Samuel Jr., and then pursuing a nursing degree at Howard University. In addition to her high academic achievements, Maegan plays softball, basketball and field hockey.

Two $5,000 scholarships were awarded to children of Ferring US employees. One was granted to Jessica Belmar of Somerset, a senior at Immaculata High School with a cumulative grade point average (GPA) of 3.72. Jessica won the 2007 New Jersey Regional Science Fair Award for Biochemistry for her project, “The effect of calcium on tomato plants.” In addition to playing the flute and baritone horn, she participates in many extracurricular activities, including the French Honor Society and Student Council. Jessica is also involved in community programs, such as working for the Ronald McDonald House.

The other winner is Collin Berndt of Upper Saddle River, who graduated from Don Bosco Prep High School in June 2008 with a cumulative GPA of 90 (out of 100). Collin attends the University of Vermont, where he double majors in finance and environmental science. At Don Bosco, he was a member of the varsity ice hockey team and Metropolitan Junior B Travel Hockey League. His extracurricular activities include serving as a volunteer at the Fire Department and Harlem soup kitchen, and 9/11 fundraising.

Ferring’s scholarship fund honors the memory of Terry McMorrow, former Vice President of Finance at Ferring for nearly a decade, until he died in April 2007 at age 51. His remarkable dedication, drive, enthusiasm and achievements were an inspiration to many company employees.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments of any manufacturer in the U.S. The Company markets MENOPUR^® (menotropins for injection, USP), BRAVELLE^® (urofollitropin for injection, purified), REPRONEX^® (menotropins for injection, USP), NOVAREL^® (chorionic gonadotropin for injection, USP) and ENDOMETRIN in the U.S. to infertility specialists and their patients. Ferring also offers the Q∙CAP™, the first and only needle-free reconstitution device, for use with its fertility treatments. Ferring’s line of orthopaedic and urology products includes EUFLEXXA™, hyaluronic acid for pain from osteoarthritis in the knee, and DEGARELIX, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of hormonally-sensitive advanced prostate cancer. Other products include: ACTHREL^® (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing’s syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED^®/DS for the relief of discomfort of the lower urinary tract. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

FDA APPROVES FERRING PHARMACEUTICALS' DEGARELIX (generic name) FOR TREATMENT OF ADVANCED PROSTATE CANCER

Thu, 26 Feb 2009 17:01:33 +0000

FOR IMMEDIATE RELEASE

CONTACT: Tara Fisher
Kovak-Likly Communications
203-762-8833, tfisher@klcpr.com

New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-term Suppression of Testosterone - a hormone that stimulates prostate cancer growth.

PARSIPPANY, NJ – December 24, 2008 – Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, indicated for patients with advanced prostate cancer. Potential trade names are still under review with the FDA. Following issuance of a trade name, Ferring Pharmaceuticals, USA will immediately begin commercialization in the U.S. On December 18, the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMEA), recommended granting a marketing authorization for degarelix in Europe. Degarelix is awaiting approval in other key global markets. It is a milestone for the company and represents Ferring’s first global product launch.

Phase III studies showed that degarelix is at least as effective as leuprolide (Lupron Depot^®) in sustaining castrate levels or lower of testosterone, and had a statistically significant faster reduction of testosterone. At Day 3 of treatment, 96% of degarelix patients achieved castrate levels of testosterone, compared with zero percent receiving leuprolide. By Day 14, 99% of degarelix patients achieved castrate levels of testosterone, compared with 18% receiving leuprolide.

In the clinical trial, prostate specific antigen (PSA) levels were also monitored as a secondary endpoint. PSA levels were lowered by 64% two weeks after administration of degarelix, 85% after one month, 95% after three months, and remained suppressed throughout the one year of treatment. These PSA results should be interpreted with caution because of the heterogeneity of the patient population studied. No evidence has shown that the rapidity of PSA decline is related to a clinical benefit.

Prostate cancer is known to grow in the presence of testosterone. Suppression of testosterone has been a treatment goal for advanced prostate cancer for many years. Surgical castration was the standard method of reducing testosterone from the 1940s until the mid-1980s when the earliest forms of medical castration, luteinizing hormone releasing hormone (LHRH) agonists, were introduced.

Degarelix is the only GnRH receptor antagonist approved by the FDA for the treatment of hormonally-sensitive advanced prostate cancer. Degarelix achieves medical castration differently than LHRH agonists, specifically by binding reversibly to GnRH receptors on cells in the pituitary gland, quickly reducing the release of gonadotropins and consequently testosterone.

“Degarelix was discovered in San Diego, developed by Ferring Pharmaceuticals in the U.S. and Europe, and in its pivotal Phase III study demonstrated both an immediate onset of action and a profound long-term suppression of testosterone and PSA,” commented Dr. Pascal Danglas, Executive Vice President Clinical & Product Development, at Ferring. “We are delighted to deliver a new treatment option for advanced prostate cancer to the medical community. Ferring has a considerable pipeline of urology products in development, and we expect to introduce additional treatment advances in the urology field in the near future.”

“Use of a GnRH receptor antagonist is a highly efficient way to stop the production of testosterone,” said Neal Shore, MD, FACS, Medical Director for Carolina Urologic Research Center, a clinical trial investigator and advisor to Ferring. “The approval of degarelix offers the medical community an effective alternative in the treatment of hormonally-sensitive prostate cancer. Now prostate cancer can be treated with immediate inhibition of the GnRH receptors, inducing rapid reduction of testosterone to castrate levels, and sustaining those levels over time, which are the goals of systemic therapy. When a patient has disease recurrence, it is always encouraging to clinicians and patients to see PSA levels fall so rapidly.”

Wayne Anderson, President and CEO Ferring Pharmaceuticals, USA added, ”We are enthusiastically preparing to enter this therapeutic area of urology. We respect the challenges physicians and patients face in their fight against prostate cancer and hope that we can help them with this new treatment option. This is a big milestone for the U.S. operating unit, and we have been carefully preparing for over two years for this launch.”

Phase III Study Results
The 12-month, randomized, open-label, parallel-group Phase III study evaluated the efficacy and safety of degarelix compared with leuprolide administered monthly over one year of prostate cancer treatment. Patients with histologically confirmed prostate cancer were randomized to either degarelix or leuprolide: a degarelix subcutaneous (under the skin) injection of 240 mg for one month with monthly maintenance doses of 80 mg (n=207) or monthly intermuscular (into the muscle) injections of leuprolide depot 7.5 mg (n=201). The primary endpoint was testosterone suppression to ≤50 ng/dL during monthly measurements from Day 28 to Day 364. Degarelix was at least as effective as leuprolide in achieving and maintaining castrate levels of testosterone.

	N	Patients with treatment responses	% (95% CI)
Degarelix 240/80 mg	207	202	97.2
Leuprolide 7.5 mb	201	194	96.4

Suppression of testosterone levels to ≤50 ng/dL occurred significantly faster in patients receiving degarelix than in those receiving leuprolide. At Day 3, 96% of patients demonstrated treatment response. In that same time period, none of the patients who received leuprolide demonstrated treatment response. Conversely, testosterone levels had increased by a median of 65% in 80% of those receiving leuprolide at Day 3.

Overall, the most commonly observed adverse reactions during degarelix therapy included injection site reactions (e.g. pain, erythema, swelling or induration), hot flushes, increased weight, fatigue, and increases in serum levels of transaminases and gammaglutamyltransferase (GGT). 99% of these observed adverse reactions were Grade 1 or 2 (mild to moderate). Specifically relating to the injection site adverse reactions, most were transient, of mild to moderate intensity, occurred primarily with the starting dose and led to few discontinuations (<1%). Grade 3 (severe) injection site reactions occurred in 2% or less of patients receiving degarelix. Degarelix is contraindicated in patients with known hypersensitivity to degarelix or to any of the product components. Degarelix is not indicated in women or pediatric patients. Long-term androgen deprivation therapy prolongs the QT interval. Physicians should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in patients taking Class IA (e.g. quinidine, procainamide) or Class III (e.g. amiodarone, sotalol) antiarrhythmic medications.

About Prostate Cancer
Prostate cancer is the most common cancer, excluding skin cancers, and the second leading cause of cancer death in American men. About one man in six will be diagnosed with prostate cancer during his lifetime, and one in 35 will die of this disease.¹ Prostate cancer develops from cells in the prostate gland that begin to grow out of control. In most cases, prostate cancer grows slowly and can remain undetected throughout a man’s life, although it can grow and spread quickly.² The four types of standard treatment are: watchful waiting, surgery, radiation therapy, and hormone therapy, also called androgen deprivation therapy (ADT). Degarelix is a new form of hormone therapy that reversibly binds to the GnRH receptors, inhibiting the production of testosterone. By suppressing the production of testosterone, tumor growth is inhibited.³

About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals offers a line of urology, orthopaedic and infertility products in the U.S. market. They include: EUFLEXXA^®, (1% sodium hyaluronic acid), BRAVELLE^® (urofollitropin for injection, purified), MENOPUR^® and REPRONEX^® (menotropins for injection, USP), NOVAREL^® (chorionic gonadotropin for injection, USP), ENDOMETRIN^® (progesterone) Vaginal Insert, ACTHREL^® (corticorelin ovine triflutate for injection), PROSED^® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), and DESMOPRESSIN. Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology and infertility. For complete prescribing information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com. # # #

WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD

Thu, 26 Feb 2009 17:01:33 +0000

Contact: Christine Stroup FOR IMMEDIATE RELEASE
Kovak-Likly Communications
(203) 762-8833 or
CStroup@KLCpr.com

Ferring Pharmaceuticals Announces
2008 My Little Miracle Essay Contest

PARSIPPANY, NJ – April 9, 2008 - If you are a parent who has successfully given birth using Ferring Pharmaceuticals’ fertility products, you can win a $10,000 education fund to support your child’s future. Eleven other education fund prizes will also be awarded. To be eligible, all you need to do is write a brief essay. The topic is: If I Knew Then What I Know Now, explaining what advice you would give to other women who are just beginning their journey to parenthood and how you would describe your success using BRAVELLE^® (urofollitropin for injection, purified) and/or MENOPUR ^® (menotropins for injection, USP) as part of your treatment plan.

Ferring is also awarding a $2,500 education fund to the runner up and $500 each to 10 honorable mention winners. Since announcing the first contest in 2004, Ferring has awarded $85,000 in education funds.

Essays should not exceed 2,000 words. They must be written in English, include the entrant’s name, address, phone number and age, as well as the child(ren)’s name(s) and age(s), and be submitted with a contest application and labeled digital photo. Entries must be postmarked by August 30, 2008. Winners will be announced at the 64th Annual Meeting of the American Society for Reproductive Medicine (ASRM)/, November 8-12, 2008.

For more details and a contest application, visit www.ferringfertility.com or www.ferringusa.com or call (203) 762-8833 and ask for the My Little Miracle Essay Contest representative.

BRAVELLE^® and MENOPUR ^®, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.8%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

The treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in
naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with BRAVELLE^® and/or MENOPUR ^® may result in multiple gestations.

Ferring’s line of orthopaedic and urology products includes EUFLEXXA™, hyaluronic acid for pain from osteoarthritis in the knee. Other products include: ACTHREL^® (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing’s syndrome; DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis; and PROSED^®/DS for the relief of discomfort of the lower urinary tract.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.
# # #
Please contact Christine Stroup for full prescribing information.

FERRING REPORTS ON ENDOMETRIN® PRESENTATIONS AT PACIFIC COAST REPRODUCTIVE SOCIETY ANNUAL MEETING

Thu, 26 Feb 2009 17:01:33 +0000

CONTACT: Andrea Preston FOR IMMEDIATE RELEASE
Kovak-Likly Communications
203-762-8833, apreston@klcpr.com

Progesterone Vaginal Supplement Studied in Largest-Ever IVF Trial in US

Rancho Mirage, CA – April 18, 2007 – Results of four studies evaluating Ferring Pharmaceuticals’ ENDOMETRIN^®, a novel progesterone vaginal insert in development for luteal phase support (supplementation to provide support for implantation and the early stages of pregnancy) in assisted reproductive technologies (ART) were presented at the 55th Annual Meeting of the Pacific Coast Reproductive Society in Rancho Mirage, CA, April 18 to 22, 2007.

ENDOMETRIN is micronized progesterone in a tablet form that is vaginally inserted with a matched applicator. Marketing applications for ENDOMETRIN for luteal phase support in ART have been filed in the United States, Hong Kong and Israel.

“ENDOMETRIN was evaluated in the largest IVF trial ever undertaken in the United States across a wide range of patient types. Results from the trial show that ENDOMETRIN provided quality luteal phase support, measured by continuing pregnancy rates, and it is administered in an easy, patient-friendly way,” said Kenneth B. Kashkin, M.D., Senior Vice President, Global Clinical Research and Development, Chief Medical Officer (U.S.), Ferring Pharmaceuticals. “Our studies also show that administering MENOPUR^® and BRAVELLE^® once a day in a single combined injection, another patient convenience, provided equivalent efficacy compared with twice-daily dosing, and excellent pregnancy rates.”

Largest-Ever IVF Trial in the United States
The activity and tolerability of ENDOMETRIN were evaluated in a multicenter, randomized, open-label, assessor-blinded trial of 1,211 women, ages 18-42, undergoing in vitro fertilization (IVF). MENOPUR (menotropins for injection, USP) and BRAVELLE (urofollitropin for injection, purified), human-derived FSH, were used for the stimulation phase of IVF, with a minimum of one vial of MENOPUR per day. The centers had the option of combining BRAVELLE and MENOPUR and administering it as one single daily injection, which was done for approximately one third of the patients (n=777). On the day of oocyte retrieval, patients were randomized to ENDOMETRIN 100 mg twice daily, ENDOMETRIN 100 mg three times daily, or an active control (progesterone vaginal gel (90 mg) QD)*. In the study, efficacy was measured by continuing pregnancy rates. An analysis was also conducted to evaluate oncedaily compared with twice-daily dosing of gonadotropins during the stimulation phase.

The results showed that ENDOMETRIN was efficacious, with no significant differences in efficacy parameters between treatment arms. Continuing pregnancy rates were 42.3 percent with ENDOMETRIN TID and 38.6 percent with ENDOMETRIN BID. The groups also showed equivalent tolerability, with no significant differences in the incidence of adverse events between groups.

Results in Harder-to-Treat Patients
The activity of ENDOMETRIN was also evaluated in harder-to-treat patients – women over age 35, or with elevated basal follicle stimulating hormone (FSH) or body mass index (BMI). Excellent continuing pregnancy rates were observed across a broad range of patient types with the use of BRAVELLE, MENOPUR and ENDOMETRIN.

Once-Daily Mixed Protocol
The trial data also demonstrated that administration of MENOPUR and BRAVELLE once a day as a single combined injection provided equal efficacy compared with twice-daily dosing, and that twice-daily dosing offers no additional patient benefits.

Parameter	Bravelle+Menopur QD N=777	Bravelle+Menopur BID N=434	p-value
Age	32.5	34.0	<0.001
BMI	25.0	24.9	0.181
Duration	10.0	10.6
Oocytes	14.0	13.4	0.225
Continuing Pregnancy (%)	41.3	40.6	0.808

Comparison With Intramuscular (IM) Progesterone
A separate study, led by Naveed Khan, M.D. at Shady Grove Fertility Reproductive Science Center in Rockville, MD, evaluated the effectiveness of vaginal progesterone supplementation with ENDOMETRIN compared with intramuscular IM progesterone supplementation. Forty patients were randomized to one of three forms of vaginal supplementation – ENDOMETRIN BID (n=12), ENDOMETRIN TID (n=11), and vaginal gel QD (n=17) – for luteal support after IVF embryo transfer for 10 weeks. Pregnancy outcomes were compared to those for patients treated with IM progesterone in the same ART center during the same time period in which patients were treated with the center’s standard protocol for luteal phase support using IM progesterone. Subjects receiving IM progesterone were matched to case cycles for age, baseline FSH, endometrial thickness on the day of hCG trigger injection, stage of embryo transfer, and number of embryos transferred. Each case cycle was matched to five control cycles, for a total of 200 control cycles.

The pregnancy rates (50 percent for vaginal, 51.5 percent IM) and live birth rates (47.5 percent vaginal, 47 percent IM) were similar between treatment groups, and there were no significant differences for any of the examined variables.

	Vaginal progesterone	IM progesterone
Number of cycles	40	200
Age (years)	35.5	35.4
FSH (IU/L)	7.3	7.4
Endometrium (mm)	12.1	11.0
ET stage (% blastocyst)	35.0	35.0
Embryos per ET	2.2	2.3
Clinical intrauterine pregnancy (per cycle)	20 (50.0%)	103 (51.5%)
1^st trimester pregnancy loss	0 (0.0%)	6 (5.8%)
2^nd trimester pregnancy loss	1 (5.0%)	3 (2.9%)
Live birth (per cycle)	19 (47.5%)	94 (47.0%)

About Luteal Support
Successful implantation of the embryo depends on adequate preparation of the endometrium, the mucous membrane lining the uterus. The corpus luteum, formed after the oocyte is released, secretes progesterone to induce secretory transformation of the endometrium. Since natural progesterone production may be compromised by in vitro fertilization (IVF), progesterone supplementation is believed to be necessary to provide the proper support for implantation and the early stages of pregnancy. Studies have shown that luteal support with progesterone after an assisted reproductive technology (ART) can result in increased pregnancy rates.
Currently available progesterone supplements come in oral, intramuscular (IM) injection, vaginal gel and suppository forms.

About BRAVELLE and MENOPUR
BRAVELLE^® (urofollitropin for injection, purified) and MENOPUR ^® (menotropins for injection, USP), like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.8%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. The treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with BRAVELLE^® and/or MENOPUR^® may result in multiple gestations.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets BRAVELLE^®, MENOPUR^®, REPRONEX^® and NOVAREL (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. Ferring also offers the Q·CAP™, the first and only needle-free reconstitution device, for use with its fertility treatments.
Ferring’s line of orthopaedic and urology products includes EUFLEXXA™, hyaluronic acid for pain from osteoarthritis in the knee. Other products include ACTHREL^® (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing’s syndrome and DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis.
The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.
# # #
*Crinone (progesterone vaginal gel) 8% is marketed by Columbia Laboratories. Please contact Andrea Preston for MENOPUR and BRAVELLE full prescribing information

COMPARATIVE STUDY SHOWS SAFER, MORE CONTROLLED STIMULATION WITH MENOPUR® THAN GONAL-f® IN OVULATION INDUCTION

Thu, 26 Feb 2009 17:01:33 +0000

CONTACT: Marilyn Seiger FOR IMMEDIATE RELEASE
Kovak-Likly Communications
203-762-8833, mseiger@klcpr.com

COMPARATIVE STUDY SHOWS SAFER, MORE CONTROLLED STIMULATION WITH MENOPUR^® THAN GONAL-f^® IN OVULATION INDUCTION
LH-Modified Follicular Development Could Improve Safety in OI and Lower Risk of Multiple Pregnancies

Suffern, NY – June 7, 2006 – A head-to-head study of MENOPUR^® (menotropins for injection, USP), highly purified human menopausal gonadotropin (HP-hMG), and Gonal-f^® (follitropin alpha for injection), recombinant follicle stimulating hormone (rFSH), demonstrated that the ovulation rate with MENOPUR^® is comparable to that obtained with rFSH in ovulation induction (OI) protocols. Of the 184 patients in the study, there were no multiple pregnancies with the MENOPUR^® group while the incidence was 12 percent in the Gonal-f group. OI therapy, which uses medication to stimulate the ovaries to produce a single follicle and induce ovulation, is the predominant treatment for anovulatory infertility.

The study suggests that the hCG-driven luteinizing hormone (LH) activity in MENOPUR^® induces a different follicular development profile compared to the use of FSH alone. This could result in a safer, more controlled stimulation cycle with a lower risk of multiple pregnancies, excessive response, and ovarian hyperstimulation syndrome (OHSS), which is excessive stimulation of the ovaries. The study is available online at http://humrep.oxfordjournals.org/cgi/reprint/del085v1 and will be published in an upcoming issue of Human Reproduction.

“These data demonstrate that the incorporation of hCG-driven LH activity in the stimulation protocol promotes single follicular development, which can lead to a reduction in multiple pregnancies and their associated complications,” said lead investigator, Prof. Peter Platteau, Center for Reproductive Medicine, Free University of Brussels. “This finding suggests that the use of hMG could result in a safer, more controlled stimulation cycle. Single follicular development and singleton pregnancy are important goals of fertility treatment, as there are substantial social, economic and health consequences of multiple pregnancies.”

About the Study
This was a randomized, open-label, assessor-blind, parallel-group, multinational OI study of 184 women, ages 18-39 years, with anovulatory infertility WHO Group II and resistant to clomiphene citrate. Patients were randomized to undergo stimulation with HP-hMG (n=91) or rFSH (n=93) using a low-dose step-up protocol. The starting dose of both treatments was 75 IU; after the first 7 days, the follicular response was evaluated and, if necessary, the dose was adjusted by 37.5 IU every 7 days for up to 6 weeks.

The ovulation rate was comparable in both groups, at 83.5 percent in the HP-hMG group and 84.9 percent in the rFSH group. Subjects in the HP-hMG group had significantly fewer intermediate-sized follicles (12-16 mm) than those in the rFSH group (1.04 and 1.91, respectively, p=0.009). This result could be responsible for the decreased estradiol levels and lack of multiple births in the MENOPUR arm. Development of a single dominant follicle was achieved by 63.7 percent in the HP-hMG group compared to 54.8 percent in the rFSH group. While there were no multiple pregnancies with HP-hMG, two of the 16 (12.5 percent) pregnancies with rFSH were multiple gestations. The singleton live birth rate was comparable.

One subject in the HP-hMG group and three subjects in the rFSH group reported OHSS. The percentage of subjects who had OHSS or cycle cancellation from an excessive response was 2.2 percent with HP-hMG and 9.8 percent with rFSH (p=0.058). The incidence of preterm birth (<37 weeks) was 27.8 percent in the rFSH group, while all infants in the HP-hMG group were born at term. The frequency and profile of adverse events was similar in both groups.

About MENOPUR^®
MENOPUR^® administered subcutaneously is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an ART (Assisted Reproductive Technology) program.

MENOPUR^® is supplied in sterile vials as a lyophilized powder or pellet. MENOPUR^® delivers 75 IU FSH and 75 IU LH activity and is supplied in a box containing five vials of medication, five vials of diluent (NDC 55566-7501-1), and five Q

NATIONWIDE SURVEY FINDS ONLY 30 PERCENT OF PATIENTS UNDERGOING INFERTILITY TREATMENT ARE ABLE TO ADMINISTER THEIR MEDICATIONS WITH ONE INJECTION PER DAY

Thu, 26 Feb 2009 17:01:32 +0000

CONTACT: Andrea Preston FOR IMMEDIATE RELEASE
Kovak-Likly Communications
203-762-8833, apreston@klcpr.com

NATIONWIDE SURVEY FINDS ONLY 30 PERCENT OF PATIENTS UNDERGOING INFERTILITY TREATMENT ARE ABLE TO ADMINISTER THEIR MEDICATIONS WITH ONE INJECTION PER DAY
Infertility Treatments Remain Complex and Anxiety-Producing for Many

SUFFERN, NY – May 30, 2006 - A new survey reveals that 79 percent of women undergoing treatment for infertility were required to use a combination of injectable medications in their most recent treatment cycle, but only 30 percent were able to administer those medications via a single injection each day. Nearly two-thirds of patients indicated that they would ask their doctor for a single injection per day treatment option if they knew it was available to fulfill their treatment protocol.

The nationwide survey, sponsored by Ferring Pharmaceuticals, was conducted online by RESOLVE: The National Infertility Association from January 15 through January 26, 2006. The majority of the 238 respondents were between the ages of 27 and 40, with nearly two-thirds in treatment for infertility more than a year. More than half of the respondents used both a needle and syringe and pen (an injection device that resembles a ball point pen) to administer their injectable medications; one-third used only a needle and syringe and 10 percent only a pen.

“We would like to see more patients who must combine their medication for their infertility treatment be able to administer their medication just once-a-day,” said William Keye, M.D., director of the Division of Reproductive Endocrinology and Infertility at William Beaumont Hospital. “With once-daily dosing, the benefits to the patient are significant – there is less anxiety, burden, teaching time and chance for error.”

As expected, more patients were anxious about administering their medication using a needle and syringe than a pen, however, patients required to use both a needle and syringe and pen experienced even greater levels of anxiety. Among this latter group, nearly 17 percent reported considerable to very severe anxiety when they had to inject their medication more than once per day.

While only two percent of all pen users discarded a pen because it failed to work properly, approximately 40 percent of pen users acknowledged they needed to discard a pen on one or more occasions because it contained insufficient medication for their next dose and 44 percent discarded a pen with medication in it at the completion of their treatment cycle. Only one-third (34 percent) of patients using the pen opted to use the diary typically accompanying it to record the amount of medication remaining in the pen. More (45 percent), however, simply chose to estimate amounts based on their daily dose.

“This survey uncovered continuing anxieties and challenges that patients undergoing treatment for infertility are facing,” said Olivier Delannoy, vice president, infertility business unit, Ferring Pharmaceuticals. “We feel it is critical for the industry to take the lead in simplifying the patient care journey and reducing hurdles that contribute to a more arduous process for the majority of those treated.”

“RESOLVE continues to encourage and support additional research into the diagnosis, treatment and emotional challenges related to infertility and reproductive health,” said Joseph C. Isaacs, president and CEO, RESOLVE. “The more we know about infertility and can simplify the treatment process, the better we can support the millions of women and men struggling to have a baby.”

General Demographics and Treatment History

The majority of respondents (83%) were between 27 and 40 years of age.
One-third of the respondents had been in treatment for less than one year; nearly two-thirds for more than one year.
More than one-third (34%) of the respondents had undergone four or more cycles of injectable medications for ovulation induction; more than half (54%) had undergone one or two IVF cycles using injectable medications.
The vast majority (79%) used multiple injectable medications in their most recent treatment cycle.
However, only 30% of the respondents were able to administer their medications in one injection per day.
Nearly two-thirds (64%) of the respondents indicated that they would ask their doctor for a single injection per day treatment option if they knew it was available.
Most patients did not request specific products (78%), however, when they did, Follistim (8%), Gonal-f (7%) and Menopur (5%) were the three most frequently requested brands.
More than half of the respondents (52%) used both a needle and syringe and pen to administer their injectable medications; one-third (34%) used a needle and syringe only; and 10% used a pen only.

About RESOLVE: The National Infertility Association
RESOLVE: The National Infertility Association is the oldest and largest consumer-based, nonprofit group in the United States providing education, advocacy and support on behalf of those struggling with infertility. Founded in 1974, RESOLVE and its network of more than 40 chapters across the U.S. handle over 1.5 million contacts each year from people seeking information and compassionate support to help them address a reproductive system disease now afflicting 7.3 million in the United States or 12.5 percent of all couples of childbearing age. For more information visit www.resolve.org.

About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals is part of the Ferring Group, a privately owned, international pharmaceutical company. The Company markets BRAVELLE^® (urofollitropin for injection, purified), MENOPUR^® (menotropins for injection, USP), REPRONEX^® (menotropins for injection, USP) and NOVAREL^® (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients, and EUFLEXXA™ (highly purified hyaluronan) for patients with pain from knee osteoarthritis. Other products include ACTHREL^® (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing’s syndrome and generic DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis.

The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888- FERRING or visit www.ferringusa.com or www.ferringfertility.com.

# # #

FERRING PHARMACEUTICALS ANNOUNCES EUFLEXXA™ LABELING EXTENDED TO INCLUDE ROOM TEMPERATURE STORAGE

Thu, 26 Feb 2009 17:01:32 +0000

CONTACT: Tara Fisher FOR IMMEDIATE RELEASE
Kovak-Likly Communications
203-762-8833, tfisher@klcpr.com

EUFLEXXA™ LABELING EXTENDED TO INCLUDE ROOM TEMPERATURE STORAGE
Ferring Debuts New Product Labeling at AAOS Annual Meeting

Suffern, NY – April 10, 2006 – Ferring Pharmaceuticals Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved the Premarket Application (PMA) supplement for EUFLEXXA™ (highly purified hyaluronan) that allows the product to be stored at room temperature, as well as refrigerated. EUFLEXXA™ is a three-injection treatment given by physicians for the pain caused by knee osteoarthritis (OA). The new labeling was introduced to the medical community at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in Chicago, March 22-26, and product reflecting this label extension is now available to the public.

EUFLEXXA™ has been extremely well received by physicians and patients alike since it was introduced in November 2005,” said Wayne Anderson, President, Ferring Pharmaceuticals Inc. “Patients are finding relief from the pain of knee osteoarthritis for the first time, after other first line treatments have failed. In fact, a head-to-head study showed that EUFLEXXA™ offers better symptom-free relief from knee OA pain than Synvisc^®, the market-leading HA therapy, with less use of simple analgesics and a lower incidence of joint effusion.1 This new labeling makes it easier for physicians to store EUFLEXXA™ and keep it available for patients.

In conjunction with this extension, the shelf life of EUFLEXXA™ will be 12 months. The newly labeled product will be designated by the same product code (sometimes referred to as NDC/HRI #) 55566-4100-1.

About EUFLEXXA™
EUFLEXXA™ (1% sodium hyaluronate) is the first and only non-avian derived* hyaluronic acid approved in the U.S. for the treatment of pain caused by knee osteoarthritis and is indicated for a three-injection treatment regimen for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. Since it is not derived from an avian source (chicken or rooster combs), the risk of related reactions is eliminated. ^2,3 In addition, EUFLEXXA™ has properties similar to the HA in healthy human synovial fluid and is free of chemical cross-linking which minimizes the risk of related reactions.^2-7

EUFLEXXA™ received approval from the U.S. Food and Drug Administration (FDA) on December 3, 2004, and became available to the public on November 8, 2005. For more information, visit www.EUFLEXXA.com.

About Hyaluronic Acid
HA is a viscous, elastic liquid that is naturally found in many tissues of the body and in high concentrations in synovial fluid. Within a joint, HA is essential to water balance, viscosity, lubrication and the structure of cartilage.⁸ In synovial fluid, HA binds to other molecules, helping it withstand weight-bearing force and movement of the joint. Inside the knee joint, HA provides a cushion to protect the joint from mechanical damage and acts as both a shock-absorbing fluid and regulator of water and metabolites.

Non-steroidal anti-inflammatory drugs (NSAIDs) are common first-line pharmacologic treatments for knee pain relief. Serious side effects and risks (ie. potentially life-threatening stomach bleeding and kidney disease) have been associated with such treatments.

The effectiveness of different treatments varies from person-to-person and with the severity of the condition. Treatment options are generally a shared decision between the patient and his/her physician with total knee replacement surgery usually sought as the last option.

About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately owned, international pharmaceutical company. Ferring’s line of orthopaedic and urology products include EUFLEXXA™, hyaluronic acid for the treatment of pain from osteoarthritis of the knee and degarelix for prostate cancer (Phase III).

Ferring also markets MENOPUR^® (menotropins for injection, USP), BRAVELLE^® (urofollitropin for injection, purified), REPRONEX^® (menotropins for injection, USP) and NOVAREL^® (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. Ferring offers the Q·CAP™, the first and only needle-free reconstitution device, for use with its fertility treatments.

Other products include ACTHREL^® (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing’s syndrome and desmopressin acetate in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis.

# # #

* Derived through bacterial fermentation
EUFLEXXA is a trademark of Ferring Pharmaceuticals Inc.
Synvisc is a registered trademark of Genzyme Corporation.

WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD

Thu, 26 Feb 2009 17:01:32 +0000

CONTACT: Christine Stroup FOR IMMEDIATE RELEASE
Kovak-Likly Communications
(203) 762-8833 or CStroup@KLCpr.com

WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD
Ferring Pharmaceuticals Announces 2006 My Little Miracle Essay Contest

If you are a mom who has successfully given birth using Ferring Pharmaceuticals’ infertility products, you can win a $10,000 education fund or one of 11 other prizes to support your child’s future. To be eligible, all you need to do is write a brief essay on your journey to achieve parenthood and its impact on your life.

Ferring’s My Little Miracle Essay Contest is open to women who have been successfully treated with BRAVELLE^® (urofollitropin for injection, purified), MENOPUR ^® (menotropins for injection, USP), REPRONEX^® (menotropins for injection, USP), or a combination of these medications. The contest celebrates the miracle of birth for these mothers who have faced infertility and continues Ferring’s tradition of providing value to their patients by offering education funds for the winners’ children.

Ferring is also awarding a $2,500 education fund to the runner up and 10 honorable mention winners will each receive $500. Since announcing the first contest in 2004, Ferring has awarded $50,000 in education funds to its winners.

Essays should not exceed 800 words, must be written in English, include the entrant’s name, address, phone number and age, as well as the child(ren)’s name and age(s) and be submitted with a contest application and labeled photo. Entries must be postmarked by June 30, 2006. Winners will be announced at the 62nd Annual Meeting of the American Society for Reproductive Medicine (ASRM), October 21-25, 2006.

For more details and a contest application visit www.ferringfertility.com or call (203) 762-8833 and ask for the My Little Miracle Essay Contest representative.

BRAVELLE^® (urofollitropin for injection, purified), MENOPUR ^® (menotropins for injection, USP) and REPRONEX^® (menotropins for injection, USP), like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0%, 3.8% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

The treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with BRAVELLE^®, MENOPUR ^® and/or REPRONEX^® may result in multiple gestations.

# # #

FERRING PHARMACEUTICALS ANNOUNCES BRUCE JENNER AS NATIONAL SPOKESPERSON FOR EUFLEXXA™

Thu, 26 Feb 2009 17:01:32 +0000

CONTACT: Tara Fisher FOR IMMEDIATE RELEASE
Kovak-Likly Communications
203-762-8833, tfisher@KLCpr.com

Olympian Bruce Jenner has suffered from the pain of knee osteoarthritis for over 10 years.

FERRING PHARMACEUTICALS ANNOUNCES BRUCE JENNER AS NATIONAL SPOKESPERSON FOR EUFLEXXA™
Olympic Gold Medal Winner is First in the U.S. to be Treated with EUFLEXXA™

Suffern, NY – February 14, 2006 – Ferring Pharmaceuticals Inc. announced today that Olympic gold medal winner Bruce Jenner will be serving as the national spokesperson for the company’s newest product, EUFLEXXA™ (highly purified hyaluronan). The announcement comes as Jenner celebrates the 30th anniversary of his remarkable achievements at the 1976 Olympic Games in Montreal. There, Jenner earned the title of “World’s Greatest Athlete” when he broke a world record by scoring 8,634 points in the decathlon. Jenner is once again making history by becoming the first person in the United States to be treated with EUFLEXXA™ for the pain caused by knee osteoarthritis (OA).

“Like a lot of people my age, I enjoy biking, golfing and playing with my kids. I have a rigorous schedule of physical activity and EUFLEXXA™ has been a part of my doctor’s recommended treatment. I felt the difference immediately and have been pain free, “said Jenner. “My doctor’s recommended treatment has even allowed me to increase my physical activity.” Jenner was treated with a three-injection regimen of EUFLEXXA™ in the fall of 2005, and has joined the ranks of patients with pain relief.

Jenner was diagnosed with OA of the knee over ten years ago. Since then he has tried a number of treatment options including exercise, other non-drug therapies, simple pain relievers and other forms of hyaluronic acid (HA) therapy.

As the national spokesperson for EUFLEXXA™, Jenner hopes to raise awareness of OA and inform those who suffer from knee pain about the treatment options that are available to them. “We are proud to have a world-class athlete like Bruce Jenner representing our product,” said Wayne C. Anderson, President, Ferring Pharmaceuticals Inc. “But more importantly, we’re happy that he is encouraging those who suffer from osteoarthritis knee pain to speak to their doctors about treatment options that may be right for them.”

About EUFLEXXA™
EUFLEXXA™ (1% sodium hyaluronate) is the first and only non-avian derived* hyaluronic acid approved in the U.S. for the treatment of pain caused by knee osteoarthritis and is indicated for a three-injection treatment regimen for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. Since it is not derived from an avian source (chicken or rooster combs), the risk of related reactions is eliminated.^1,2 In addition, EUFLEXXA™ has properties similar to the HA in healthy human synovial fluid and is free of chemical cross-linking which minimizes the risk of related reactions.^1-6

About Hyaluronic Acid
HA is a viscous, elastic liquid that is naturally found in many tissues of the body and in high concentrations in joint cartilage and synovial fluid. Within a joint, HA is essential to water balance, viscosity, lubrication and the structure of cartilage.⁷ In cartilage, HA binds to other molecules, helping it withstand weight-bearing force and movement of the joint. Inside the knee joint, HA provides a cushion to protect the joint from mechanical damage and acts as both a shock-absorbing fluid and regulator of water and metabolites.

About Bruce Jenner
Bruce Jenner earned the title “World’s Greatest Athlete” after winning the gold medal and breaking the world record by scoring 8,634 points in the decathlon at the 1976 Olympics in Montreal. Since then, he has become a motivational speaker, sports commentator, TV personality, actor, producer, author, entrepreneur, and commercial spokesperson. Jenner is also a supporter of many nonprofit organizations and serves on numerous advisory boards, including the Special Olympics, the National Dyslexia Research Foundation, and The Dream Foundation which grants wishes to terminally ill adults.

In addition to being a special correspondent on “Good Morning America” for seven years, he has been a commentator for many network sports shows, and authored two books, including Finding the Champion Within. Sports continue to be an important part of Bruce Jenner’s life. He is an avid golfer and mountain bike rider, a commercially rated pilot who flies his own jet and a professional racecar driver for the Senior Championship Racing Association and in Grand Prix events around the world. Most recently, Jenner has returned to competition as a contestant on the hit television show Skating with Celebrities. Jenner lives in Los Angeles, CA, with his wife Kris and their six children.
# # #
* Derived through bacterial fermentation

HEAD-TO-HEAD STUDY SHOWS EUFLEXXA™ HAS GREATER TOLERABILITY COMPARED TO SYNVISC® FOR OSTEOARTHRITIS KNEE PAIN

Thu, 26 Feb 2009 17:01:32 +0000

CONTACT: Tara Fisher FOR IMMEDIATE RELEASE
Kovak-Likly Communications
203-762-8833, tfisher@klcpr.com

HEAD-TO-HEAD STUDY SHOWS EUFLEXXA™ HAS GREATER TOLERABILITY COMPARED TO SYNVISC^® FOR OSTEOARTHRITIS KNEE PAIN
Significantly More Patients Symptom-Free, Lower Incidence of Joint Effusions

Suffern, NY – February 13, 2006 – An important head-to-head study has demonstrated the efficacy and greater tolerability of EUFLEXXA™ (highly purified hyaluronan) compared to Synvisc^®*, an avian-derived hyaluronan and the leading hyaluronic acid (HA) product in its class for the treatment of osteoarthritis (OA) knee pain.1 In the 12-week trial of 321 patients, EUFLEXXA™ showed statistically significant advantages over Synvisc: more patients treated with EUFLEXXA™ were symptom-free (p=0.038), there was a lower incidence of joint effusion (p=0.0015), fewer patients required supplemental simple analgesics (p=0.013), and more patients reported being “very satisfied” (p=0.03). The study was published in the February 2006 issue of Osteoarthritis and Cartilage.

EUFLEXXA™ is the first and only hyaluronic acid (HA) approved in the U.S. for the treatment of the pain of knee osteoarthritis that is not derived from an avian source** (chicken or rooster combs). This eliminates the risk of related reactions.2,3 EUFLEXXA™ is a three-injection treatment regimen indicated for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. The goal of HA therapy is to reduce pain and improve physical function by replenishing the HA in human synovial fluid (fluid in joints). In OA, this fluid becomes thinner, leading to a decrease in elasticity and viscosity.

“This study shows that EUFLEXXA™ offers better symptom-free relief from OA pain over a 12-week period than the market-leading HA therapy with less use of simple analgesics,” said Wayne Anderson, President, Ferring Pharmaceuticals Inc. “For the growing number of Americans who live with the pain caused by knee osteoarthritis, this study demonstrates the greater tolerability of EUFLEXXA™ compared to the leading therapy in its class.”

About the Study
In a prospective, multicenter, randomized, double-blind controlled trial, 321 patients with confirmed knee osteoarthritis were randomized to treatment with either EUFLEXXA™ (n=160) or Synvisc (n=161). The Western Ontario McMaster Universities Osteoarthritis (WOMAC) Index pain subscale was the primary efficacy measure. Both products were administered as a course of three weekly injections, with follow-up evaluations at weeks 3, 6 and 12. Both treatment groups experienced statistically significant improvements from baseline (p=0.0001).

EUFLEXXA™ (WOMAC pain score = 29.8 mm (-61.6%)) was shown to be comparable in efficacy to Synvisc (WOMAC pain score = 28.8 mm (-54.9%)).1 At the study endpoint, 63% of patients treated with EUFLEXXA™ were symptom-free compared with 52% of those treated with Synvisc (p=0.038), as determined by a VAS (100-mm visual analog scale) score of <20 for the average of the five WOMAC pain questions. ¹

EUFLEXXA™ also showed a significant advantage over Synvisc in the number of joint effusions (p=0.0015), patients requiring supplemental simple analgesics (p=0.013), and patient satisfaction (p=0.03). For patient satisfaction, 50% of EUFLEXXA™ patients were ‘very satisfied’ with treatment results compared to 37% for the Synvisc group. A subanalysis performed on patients with unilateral OA found that only 49% of patients treated with EUFLEXXA™ used supplemental simple analgesics compared to 82% of those treated with Synvisc (p=0.001). ¹

About EUFLEXXA™
EUFLEXXA™ (1% sodium hyaluronate) is the first and only non-avian-derived hyaluronic acid approved in the U.S. for the treatment of pain caused by knee osteoarthritis. The process used to manufacture EUFLEXXA™ results in ultra-high-purity HA with properties similar to the HA in healthy human synovial fluid. EUFLEXXA™ is also free of chemical cross-linking, which minimizes the risk of related reactions.^2-7

About Hyaluronic Acid
HA is a viscous, elastic liquid that is naturally found in many tissues of the body and in high concentrations in joint cartilage and synovial fluid. Within a joint, HA is essential to water balance, viscosity, lubrication and the structure of cartilage.⁸ In cartilage, HA binds to other molecules, helping it withstand weight-bearing force and movement of the joint. Inside the knee joint, HA provides a cushion to protect the joint from mechanical damage and acts as both a shock-absorbing fluid and regulator of water and metabolites.

Non-steroidal anti-inflammatory drugs (NSAIDs) are common first-line pharmacologic treatments for knee pain relief. Serious side effects and risks (i.e. potentially life-threatening stomach bleeding and kidney disease) have been associated with such treatments. The effectiveness of different treatments varies from person-to-person and with the severity of the condition. Treatment options are generally a shared decision between the patient and his/her physician with total knee replacement surgery usually sought as the last option.

About Ferring Pharmaceuticals Inc. Ferring Pharmaceuticals Inc., part of the Ferring Group, is a privately owned, international pharmaceutical company. Ferring’s line of orthopaedic and urology products includes EUFLEXXA™, hyaluronic acid for the treatment of pain from osteoarthritis of the knee and degarelix for prostate cancer (Phase III).

# # #
* Synvisc is a registered trademark of Genzyme Corporation.
** Derived through bacterial fermentation

FERRING PHARMACEUTICALS ANNOUNCES LAUNCH OF EUFLEXXA™ FOR OSTEOARTHRITIS KNEE PAIN

Thu, 26 Feb 2009 17:01:32 +0000

Contact: Kelly Laban FOR IMMEDIATE RELEASE
Kovak-Likly Communications
(203) 762-8833 x15 or KLaban@KLCpr.com

Ferring Pharmaceuticals launches EUFLEXXA™ (highly purified hyaluronan), a new treatment for the pain caused by knee osteoarthritis that provides proven safety and efficacy with more patients symptom-free at the end of a 12-week study period than the leading therapy in its class.*
*Osteoarthritis and Cartilage; in press.

FERRING PHARMACEUTICALS ANNOUNCES LAUNCH OF EUFLEXXA™ FOR OSTEOARTHRITIS KNEE PAIN
More Patients Treated with EUFLEXXA™ Symptom-Free at End of 12-Week Study Than Those Treated With the Leading Therapy in its Class

Suffern, NY – November 14, 2005 – Ferring Pharmaceuticals Inc. announced today the launch of EUFLEXXA™ (highly purified hyaluronan) for the treatment of pain caused by knee osteoarthritis (OA). It is the first and only non-avian* derived hyaluronic acid (HA) indicated for a three-injection treatment regimen for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. At the end of a 12-week study, significantly more patients treated with EUFLEXXA™ were symptom-free (p=0.038) than those treated with Synvisc**, the leading HA product in its class.₁

“EUFLEXXA™ is a new treatment option that can help millions of people who live with painful knees,” said Wayne C. Anderson, president, Ferring Pharmaceuticals. “It is proven to offer better drug-free symptom relief over a 12-week period than the current leading HA therapy. Additonally, it offers proven safety and efficacy with significantly fewer joint effusions and less use of simple analgesics than Synvisc. Not surprisingly, patients reported higher satisfaction with EUFLEXXA™.”

Clinical Advantages
In a prospective, multicenter, randomized, double-blind controlled trial, 321 patients with confirmed knee osteoarthritis were randomized to treatment with either EUFLEXXA™ (n=160) or Synvisc (n=161). The Western Ontario McMaster Universities Osteoarthritis (WOMAC) Index pain subscale was the primary efficacy measure. Both products were administered as a course of three weekly injections, with follow-up evaluations at weeks 3, 6 and 12. Both treatment groups experienced statistically significant improvements from baseline (p=0.0001). EUFLEXXA™ (WOMAC pain score = 29.8 mm (-61.6%)) was shown to be comparable in efficacy to Synvisc (WOMAC pain score = 28.8 mm (-54.9%)).1 At the study endpoint, 63% of patients treated with EUFLEXXA™ were symptom-free compared with 52% of those treated with Synvisc (p=0.038), as determined by a VAS (100-mm visual analog scale) score of <20 for the average of the five WOMAC pain questions.₁
EUFLEXXA™ also showed a significant advantage over Synvisc in the number of patients requiring supplemental simple analgesics (p=0.013), joint effusion (p=0.0015) and patient satisfaction (p=0.03). For patient satisfaction, 50% of EUFLEXXA™ patients were ‘very satisfied’ with treatment results compared to 37% for the Synvisc group. A subanalysis performed on patients with unilateral OA found that only 49% of patients treated with EUFLEXXA™ used supplemental simple analgesics compared to 82% of those treated with Synvisc (p=0.001).₁

About EUFLEXXA™
EUFLEXXA™ is the first and only non-avian derived hyaluronic acid approved in the U.S. for the treatment of pain caused by knee osteoarthritis. Since it is not derived from an avian source (chicken or rooster combs), the risk of related reactions is eliminated.2,3 In addition, the process used to manufacture EUFLEXXA™ results in ultra-high-purity HA with properties similar to the HA in human synovial fluid. EUFLEXXA™ is also free of chemical crosslinking which minimizes the risk of related reactions._2-7

EUFLEXXA™ received approval from the U.S. Food and Drug Administration (FDA) on December 3, 2004, and is also approved in Israel and the European Union. Ferring acquired the product in July 2005 as part of its acquisition of the global biologics manufacturing business of Savient Pharmaceuticals, Inc.

About Hyaluronic Acid
HA is a viscous, elastic liquid that is naturally found in many tissues of the body and in high concentrations in joint cartilage and synovial fluid. Within a joint, HA is essential to water balance, viscosity, lubrication and the structure of cartilage.8 In cartilage, HA binds to other molecules, helping it withstand weight-bearing force and movement of the joint. Inside the knee joint, HA provides a cushion to protect the joint from mechanical damage and acts as both a shock-absorbing fluid and regulator of water and metabolites.

Osteoarthritis and the General Population
The Arthritis Foundation estimates that 66 million Americans are affected by arthritis, half of whom are unaware of available treatments, and that the disease costs the U.S. economy more than $86.2 billion annually. The Foundation also estimates that 21 million American adults suffer from osteoarthritis.9 Osteoarthritis, a form of arthritis, affects certain parts of the body, most commonly the knee. Over time, articular cartilage in the knee loses elasticity and becomes worn. As a result, the bony surfaces of the joint can grind together and eventually wear the cartilage away entirely. This leads to symptoms of pain, stiffness and impaired joint movement. There are a wide range of treatment options for knee OA, including behavior modification, drug therapy, injections within the joint and knee replacement surgery. Non-steroidal anti-inflammatory drugs (NSAIDs) are common first-line pharmacologic treatments for knee pain relief. Serious side effects and risks (ie. potentially life-threatening stomach bleeding and kidney disease) have been associated with such treatments. The effectiveness of different treatments varies from person-to-person and with the severity of the condition. Treatment options are generally a shared decision between the patient and his/her physician with total knee replacement surgery usually sought as the last option.

Other products include ACTHREL^® (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing’s syndrome and generic desmopressin acetate in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, visit www.FerringUSA.com.

# # #
* Derived through bacterial fermentation
** Synvisc is a registered trademark of Genzyme Corporation.

FERRING PHARMACEUTICALS OBTAINS RIGHTS TO EUFLEXXA™

Thu, 26 Feb 2009 17:01:32 +0000

Enters Co-Promotion Agreement with Savient

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 x15 or KLaban@KLCpr.com

Suffern, NY – July 19, 2005 – Ferring Pharmaceuticals Inc. announced today that it has entered into an agreement to market EUFLEXXA™, a novel, non-avian-derived biologic formulation of hyaluronic acid for the amelioration of knee pain due to osteoarthritis. This agreement forms part of a broader transaction whereby the Ferring Group acquired the global biologics manufacturing business of Savient Pharmaceuticals, Inc., including the worldwide rights to EUFLEXXA.

“This agreement represents an additional specialty marketing opportunity that expands our product line beyond infertility,” said Wayne Anderson, president of Ferring Pharmaceuticals. “It is in keeping with our corporate strategy of niche marketing specialty products with manageable physician prescribing audiences.”

EUFLEXXA is the first and only non-avian-derived biologic formulation of hyaluronic acid approved in the U.S. for osteoarthritis of the knee. Under the agreement, Ferring and Savient, the developers of the product, will jointly market EUFLEXXA, which is expected to launch in Q4 2005. Ferring will be forming a specialist field force for this purpose.

About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc., part of the Ferring Group, a privately owned, international pharmaceutical company, markets Menopur^{^®} (menotropins for injection, USP), Bravelle^{^®} (urofollitropin for injection, purified), Repronex^{^®} (menotropins for injection, USP)and Novarel^{^®} (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. Ferring also offers the Q∙CAP™, the first and only needle-free reconstitution device, for use with its fertility treatments. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, visit www.ferringusa.com.

# # #

WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD

Thu, 26 Feb 2009 17:01:32 +0000

Ferring Pharmaceuticals Announces 2005 My Little Miracle Essay Contest

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 x15 or KLaban@KLCpr.com

Ferring’s My Little Miracle Essay Contest is open to women who have been successfully treated with BRAVELLE^® (urofollitropin for injection, purified), REPRONEX^® (menotropins for injection, USP) or a combination of both. The contest celebrates the miracles of their children’s births and continues Ferring’s tradition of providing value to their patients by offering education funds for the winners’ children.

Ferring is also awarding a $5,000 education fund for the runner up and 10 honorable mention winners will each receive $1,000.

Essays should not exceed 800 words, must be written in English, include the entrant’s name, address, phone number and age, as well as the child(ren)’s name and age(s) and be submitted with a contest application and labeled photo. Entries must be postmarked by August 30, 2005. Winners will be announced at the 61st Annual Meeting of the American Society for Reproductive Medicine, October 15 - 19, 2005, at the Palais de Congrès in Montreal, Quebec, Canada.

For more details and a contest application visit www.ferringfertility.com, www.ferringusa.com or call (203) 762-8833 and ask for the My Little Miracle Essay Contest representative.

BRAVELLE^® (urofollitropin for injection, purified) and REPRONEX^® (menotropins for injection, USP), like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with BRAVELLE^® and/ or REPRONEX^® may result in multiple gestations.

# # #

FERRING PHARMACEUTICALS APPOINTS OLIVIER DELANNOY AS VICE PRESIDENT, INFERTILITY BUSINESS UNIT

Thu, 26 Feb 2009 17:01:32 +0000

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 x15 or KLaban@KLCpr.com

Pictured: Olivier A. Delannoy, appointed vice president, Infertility Business Unit for Ferring Pharmaceuticals.

Suffern, NY – May 11, 2005 – Ferring Pharmaceuticals Inc. announced that Olivier A. Delannoy has been appointed vice president, Infertility Business Unit. In his new role, Delannoy will be responsible for the development and implementation of marketing and sales strategies for Ferring’s line of infertility products.

“Olivier has a proven track record within our organization,” said Wayne Anderson, president. “His extensive experience in the infertility market, coupled with his ability to translate strategy into measurable outcomes, make him uniquely suited to lead this business unit into the future.”

For the past two years, Delannoy served as vice president of sales, and prior to that was executive director of marketing, having joined Ferring in this capacity in March 1999. Before joining Ferring, Delannoy held management positions at several pharmaceutical industry firms, both in France and the U.S. In his new capacity, Delannoy is responsible for both the marketing and sales of BRAVELLE^® (urofollitropin for injection, purified), MENOPUR^® (menotropins for injection, USP), REPRONEX^® (menotropins for injection, USP) and NOVAREL^® (chorionic gonadotropin for injection, USP).

About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc., part of the Ferring Group, a privately owned, international pharmaceutical company, markets MENOPUR^® (menotropins for injection, USP), BRAVELLE^® (urofollitropin for injection, purified), REPRONEX^® (menotropins for injection, USP) and NOVAREL™ (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. Ferring also offers the Q∙CAP™, the first and only needle-free reconstitution device, for use with its fertility treatments. Ferring’s line of orthopedic and urology products include NUFLEXXA™, hyaluronic acid for pain from osteoarthritis in the knee and DEGARELIX for prostate cancer (Phase III). Other products include ACTHREL^® (corticorelin ovine triflutate for injection) for the differential diagnosis of Cushing’s syndrome and generic DESMOPRESSIN ACETATE in injectable and rhinal tube forms for the treatment of diabetes insipidus and primary nocturnal enuresis. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, visit www.ferringusa.com.

# # #

FERRING PHARMACEUTICALS APPOINTS WILLIAM GARBARINI AS SENIOR DIRECTOR OF MARKETING

Thu, 26 Feb 2009 17:01:32 +0000

Responsible for Marketing for Newly Created Orthopedics/Urology Business Unit

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 x15 or KLaban@KLCpr.com

Pictured: William N. Garbarini, Jr., appointed senior director of marketing for the Orthopedics/Urology Business Unit for Ferring Pharmaceuticals

Suffern, NY – May 11, 2005 – Ferring Pharmaceuticals Inc. announced that William N. Garbarini, Jr. has been appointed senior director of marketing for its new Orthopedics/Urology Business Unit. In his new role, Garbarini will be responsible for the strategic direction and implementation of marketing programs for products with significant growth potential in these therapeutic areas.

“Bill excelled in his role as director of marketing for the infertility product line and in his responsibilities for the company’s out-license relationships,” said Wayne Anderson, president. “With his proven track record, we are confident that he will lead the newly created business unit’s marketing efforts to great success.”

In his new capacity, Garbarini is responsible for marketing NUFLEXXA™, an injectable hyaluronic acid for pain from knee osteoarthritis. He will continue to be responsible for the out- license relationships of DDAVP (Aventis) and Pentasa (Shire). Garbarini joined Ferring in 2001 as product director. In 2002, he was promoted to director of marketing for Ferring’s infertility products, and was also responsible for the out-license relationships of DDAVP and Pentasa.

Prior to joining Ferring, Garbarini was director, client services for Caresoft, Inc. and product manager for the Proventil^® family of inhaled asthma medications at Schering-Plough Corporation/ Key Pharmaceuticals.

# # #

FERRING PHARMACEUTICALS ANNOUNCES LAUNCH OF NEW TREATMENT FOR INFERTILITY

Thu, 26 Feb 2009 17:01:32 +0000

MENOPUR^® (menotropins for injection, USP) First Gonadotropin to Receive FDA Approval Based on Pregnancy Rates

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 x15 or KLaban@KLCpr.com

Ferring Pharmaceuticals announces the launch of MENOPUR^® (menotropins for injection, USP), which recently received a New Drug Application approval from the U.S. Food and Drug Administration for subcutaneous injection for patients participating in Assisted Reproductive Technology (ART). MENOPUR^® is the first and only gonadotropin to be approved on the basis of pregnancy rates.

Suffern, NY – April 11, 2005 – Ferring Pharmaceuticals announced today the launch of MENOPUR^® (menotropins for injection, USP), a purified human menopausal gonadotropin (hMG) indicated for the development of multiple follicles and pregnancy in patients undergoing Assisted Reproductive Technology (ART), such as in vitro fertilization (IVF).

MENOPUR^® is the first and only fertility treatment approved by the FDA on the basis of pregnancy rates; all other currently marketed gonadotropins gained FDA clearance on the basis of oocytes retrieved. MENOPUR^® is a preparation of naturally derived gonadotropins that has undergone an exacting purification process. In clinical studies, it was shown to be comparable in efficacy to recombinant FSH while demonstrating fewer injection site reactions than the currently available hMG.

“Human menopausal gonadotropins have been the cornerstone of fertility treatment for nearly 50 years,” said Wayne Anderson, President, Ferring Pharmaceuticals. “In fact, they are the standard by which all subsequent gonadotropins have been measured. MENOPUR^® combines the proven track record of traditional hMGs with improved administration tolerability due to its high level of purity.”

MENOPUR^®, which received approval from the U.S. Food and Drug Administration (FDA) on October 29, 2004, contains equal amounts of follicle stimulating hormone (FSH) and luteinizing hormone (LH).

Pregnancy Outcomes Comparable to rFSH
In a prospective, comparative, multinational, randomized, parallel-group, multicenter, open-label trial comparing subcutaneous administration of MENOPUR^® and follitropin, 727 patients were randomized to receive treatment with MENOPUR^® (n=373) or Gonal-f^® (n=354). The primary efficacy endpoint was ongoing pregnancy rate following IVF or IVF with intracytoplasmic sperm injection (ICSI) treatment.

Ongoing pregnancy rate following IVF or IVF/ICSI treatment/*

Results showed that ongoing pregnancy rates for MENOPUR^® (menotropins for injection, USP) were comparable to those of recombinant FSH.

Improved Administration Tolerability
In a randomized, open-label, multicenter, comparative clinical trial, 190 infertile female patients undergoing ovarian stimulation to produce multiple follicles for IVF with embryo transfer (ET) were randomized to receive either MENOPUR^® SC (n=61), MENOPUR^® IM (n=65) or REPRONEX^® (menotropins for injection, USP) (n=64) treatment. MENOPUR^®, administered both SC and IM, was shown to result in significantly fewer injection site reactions (p=0.001) and fewer injection site reactions with welts and/ or inflammation (p=0.001) than REPRONEX^®.

Fewer injection site reactions than REPRONEX^®2

Parameter	MENOPUR ^® SC (n=61)	MENOPUR ^® IM (n=65)	REPRONEX ^® SC (n=64)	P Value
	———————No. of Patients (%)——————–
Injection site reactions	4 (6.6)	2 (3.1)	22 (34.4)	0.001
Injection site reactions with welts/ inflammation	0	0	8 (12.5)	0.001

“Human menopausal gonadotropins are a critical component of many Assisted Reproductive Technology treatment protocols,” said William Keye, M.D., Director, division of reproductive endocrinology and IVF programs, department of obstetrics and gynecology, William Beaumont Hospital. “This new, improved hMG formulation provides an important benefit for patients who experience discomfort caused by injecting their hMG medication.”

**About MENOPUR^® (menotropins for injection, USP) and REPRONEX^® (menotropins for injection, USP)**

MENOPUR^® is used to stimulate the development of multiple follicles and pregnancy in women participating in an Assisted Reproductive Technology (ART) program whose ovaries are unable to produce eggs for functional reasons, rather than due to primary ovarian failure.

MENOPUR^® and REPRONEX ^®, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 3.8% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with MENOPUR^® and/ or REPRONEX^® may result in multiple gestations.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets MENOPUR^®, BRAVELLE^® (urofollitropin for injection, purified), REPRONEX^® and NOVAREL™ (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. Ferring also offers the Q∙CAP™, the first and only needle-free reconstitution device, for use with its fertility treatments. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

# # #

*Gonal-f is a registered trademark of Serono Laboratories.

**See attached full prescribing information.

MICHAEL SECKLER APPOINTED NATIONAL SALES DIRECTOR FOR FERRING PHARMACEUTICALS

Thu, 26 Feb 2009 17:01:32 +0000

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 x15 or KLaban@KLCpr.com

Pictured: Michael D. Seckler, appointed national sales director for Ferring Pharmaceuticals

Suffern, NY – January 11, 2005 – Ferring Pharmaceuticals announced today the appointment of Michael Seckler, of Warren, NJ, to national sales director. Seckler joined the Company in February 2003 as district manager, eastern states. In his new role, he will be responsible for successful implementation of the sales strategy for Ferring’s product line.

“Seckler excelled as a district manager, leading his district to an unprecedented performance level in the East,” said Olivier Delannoy, vice president, sales, Ferring Pharmaceuticals. “We are confident that his dedication and strong leadership ability will ensure success in his new position.”

Prior to joining Ferring, Seckler was a specialty district manager for Pharmacia. He previously held the director of sales position at Caresoft and spent 10 years at Schering Plough, where he held a variety of positions, including district manager; product manager; and manager, managed care sales training.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle^® (urofollitropin for injection, purified), Repronex^® (menotropins for injections, USP) and Novarel™ (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients.

Ferring also offers the Q∙Cap™, the first needle-free reconstitution device, for use with its line of fertility treatments. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

# # #

LOCAL WOMAN WINS $1,000 FOR HER 19-MONTH-OLD SON

Thu, 26 Feb 2009 17:01:32 +0000

Monroe Resident Wins Honorable Mention Prize for Ferring’s My Little Miracle Essay Contest

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 x15 or KLaban@KLCpr.com

Pictured: David Reese Callicott, 19-month-old son of Lisa Callicott, honorable mention winner of Ferring Pharmaceutical’s My Little Miracle Essay Contest. Lisa’s $1,000 prize will be placed in a 529 education fund for David’s future education. David was born with the help of Bravelle™ (urofollitropin for injection, purified) – one of Ferring’s fertility treatments.

Monroe, LA – December 9, 2004 – Lisa Callicott of Monroe received a $1,000 honorable mention prize from Ferring Pharmaceuticals for her entry in the Company’s My Little Miracle Essay Contest. Lisa’s entry, Our Miraculous Story, chronicled the long path to her son’s birth. The prize money will be deposited into an education fund for David Reese, her 19-month-old son born with the help of Bravelle™ (urofollitropin for injection, purified) – one of Ferring’s fertility treatments.

“We have been blessed now by Ferring for a third time! The first two, and most important, were the help they provided in conceiving our two sons. With Ferring’s help, we are expecting the birth of our second son in late March of 2005,” said Lisa Callicott. “And we are also thrilled to start this education fund for David and we thank Ferring for their contribution. Our lives have been forever changed thanks to Ferring and our physician – Dr. Dunn.”

“We are delighted to offer this program to help fertility patients contribute to their children’s future,” said Wayne Anderson, president, Ferring Pharmaceuticals. “Ferring is committed to providing patients with safe, effective and affordable fertility treatments. This program is an extension of Ferring’s support of its patients.”

The My Little Miracle Essay Contest celebrated the births of children made possible through Ferring’s fertility treatments, Bravelle™ (urofollitropin for injection, purified) and Repronex™ (menotropins for injection, USP). Ferring awarded $25,000 in education funds to 12 winners from around the country.

About the Callicotts, their First Miracle, and their Miracle to come…

The Callicotts met in college thirteen years ago. When married, they began trying to conceive almost immediately. After a year and a half of unsuccessfully trying to conceive on their own, the Callicotts sought help. The couple felt restricted in their treatment options since their insurance would not cover all of the medications that their physician, Dr. Randall Dunn, Obstetrical and Gynecological Associates, P.A., of Houston, Texas, wanted to prescribe. After several failed attempts and despite the lack of insurance coverage for certain medications, the Callicotts decided to try one cycle with the help of Bravelle™. In her essay, Lisa speaks of her experience:

On August 14th, we got the call – we were pregnant!! We found out quickly [that] it was only one baby and everything proceeded as normal. … On the 102nd month of trying, Bravelle™, on the first try, helped me conceive! On April 10, 2003, our beautiful son, David Reese, was born. Our wonderful story doesn’t stop there! In the spring of 2004 … we decided to try for a second baby. We only had the funds to try one time and in July 2004 we did a round of Bravelle™. You could have knocked me over with a feather when the doctor’s office called to say I was pregnant. Out of nine+ years of trying to conceive, with only two cycles of Bravelle™, I had TWO successful pregnancies!! We have yet to meet our latest miracle, but know that he/she will be another blessing … Looking back, I can hardly remember the years of tears and heartache that passed. I cannot explain how the birth of David erased all those painful memories.

With the help of Bravelle™, Lisa and her husband Rob are expecting their second child in late March 2005.

**About Bravelle™ and Repronex™**

Bravelle™ (urofollitropin for injection, purified), a highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to two percent LH activity. Bravelle™, administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression. Bravelle™, administered SC in conjunction with hCG, is also indicated for multiple follicular development during ART cycles in patients who have previously received pituitary suppression.

Repronex™ (menotropins for injection, USP) is the only human menopausal gonadotropin (hMG) on the market in the U.S. and is approved for both subcutaneous and intramuscular administration.

Bravelle™ and Repronex™, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including ovarian hyperstimulation syndrome (OHSS) (incidence of 6.0% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with Repronex™ and/ or Bravelle™ may result in multiple gestations.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex™ and Novarel™ (chorionic gonadotropin for injection, USP) in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

# # #

For full prescribing information for Bravelle™ and/ or Repronex™, please contact Kelly Laban.

FAMILY BEGINNINGS CELEBRATES WITH ITS PATIENTS NAMED AS WINNERS OF FERRING'S MY LITTLE MIRACLE ESSAY CONTEST

Thu, 26 Feb 2009 17:01:31 +0000

Ferring Presents $3,000 in Prizes to Honorable Mention Winners

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 x15 or KLaban@KLCpr.com

Krissy Schenck, endocrine and reproductive specialist, Ferring Pharmaceuticals, presents honorable mention winners of its My Little Miracle Essay Contest each with a $1,000 education fund for their children born with the help of the Company’s fertility treatments.

Pictured from left to right: Back row: James G. Donahue, M.D., Family Beginnings; Kenneth King; Krissy Schenck, Ferring Pharmaceuticals; Wayne Borton holding Brooke; Laurent Euzen holding Jean-Luc. Front row: Thalia King holding Katherine Elizabeth; Christine Borton holding Alex and Carter; Eileen Euzen holding Ronan.

INDIANAPOLIS – November 15, 2004 – Family Beginnings, PC, announced today that three of its patients each received a $1,000 honorable mention prize from Ferring Pharmaceuticals for their entries in Ferring’s My Little Miracle Essay Contest. Krissy Schenck, endocrine and reproductive specialist, Ferring Pharmaceuticals, presented Christine Borton, Eileen Euzen and Thalia King each with a check to be deposited into education funds for their children born with the help of Ferring’s fertility treatments. The presentations were made on November 12th at the Family Beginnings office in Indianapolis.

“We couldn’t be more proud of our family,” said Christine Borton. “We are grateful to Ferring Pharmaceuticals for the scholarship funds.”

“I am very excited and honored that Ferring chose my essay to receive one of the $1,000 prizes for the My Little Miracle Essay Contest. As I sat down to write my essay, I found myself flooded with so many of the feelings and memories that my husband and I had experienced on our journey to become parents,” added Eileen Euzen. “It was a joy to write the essay, and the fact that I was able to win a $1,000 educational fund for my boys just adds to that joy.”

“I was completely thrilled to learn I had won honorable mention and a scholarship for my little girl,” added Thalia King. “I had a wonderful time writing the essay and this is just the icing on the cake!”

“I am delighted that three of my patients have been selected as honorable mention winners. Ferring’s unique program helps these families begin to plan for their children’s futures,” added James G. Donahue, M.D., Family Beginnings, PC. “For every patient, we must individualize treatment protocols. Some patients produce better eggs when stimulated with LH containing drugs. The cost is about half of the recombinant drugs and the results are very good. Additionally, our in vitro fertilization (IVF) procedure cost is only $3,500, which makes the technology much more affordable.”

“Ferring is delighted to offer this program to help fertility patients contribute to their children’s future,” added Krissy Schenck, reproductive and endocrine specialist, Ferring Pharmaceuticals. “Ferring is committed to providing patients with safe, effective and affordable fertility treatments. The My Little Miracle Essay Contest is an extension of Ferring’s support of its patients.”

The Contest Winners

The Bortons unsuccessfully tried to conceive for seven years. On Christmas Eve 2002, Christine told her husband, Wayne, that she could not bear another Christmas without a child. Twins ran in Christine’s family, but she was unable to conceive naturally. They applied for adoption and soon discovered that their daughter, Brooke, had been born in China and that she would be home by Christmas 2003. The Bortons wanted their daughter to have siblings, so they called their physician, Dr. James Donahue, to see if any new medications had been approved that might be helpful. He informed her that a new medication by the name of Bravelle™ (urofollitropin for injection, purified) had been approved and he was having great success with it. They scheduled an appointment. In her essay, Christine speaks of her experience:

[With] the first three in vitro [fertilization] attempts two years earlier, I had not stimulated well for my age and had poor quality embryos. This time we used a new protocol [with] Bravelle™, which the doctor believed would provide better egg quality, and therefore better embryo quality. On the first try with Bravelle™ we found out [that] we were pregnant. Our first ultrasound showed a healthy heartbeat. A month later we were astonished when our doctor found two heartbeats, and the day before Wayne left for China to … get Brooke, we found out we were having twin boys (Alex and Carter). Our family couldn’t be more perfect … This Christmas is promising to be the best Christmas ever, and we couldn’t have planned it better.

The Euzens tried unsuccessfully to conceive for almost four years; after two years of trying on their own, they decided to consult a physician. With continued heartaches, the Euzens endured many attempts to achieve pregnancy with the help of fertility treatments. After two cycles of in vitro fertilization (IVF), Dr. Donahue suggested a new protocol with Bravelle™ and Repronex™ (menotropins for injection, USP). In her essay, Eileen speaks of her experience:

[With Bravelle™ and Repronex™], I had my best follicle stimulation. … When we saw the photograph of our four little embryos, we were amazed to see how the miracle of modern medicine had helped us to create these little miracles of life. Soon thereafter, God answered ‘yes’ to my prayers, and we found out that I was pregnant with twins. My pregnancy went well, and I loved being pregnant. I still cherish every moment of that miraculous process. During week 38 of my pregnancy, I delivered two big, healthy boys – Jean-Luc (6 lbs., 1 oz.) and Ronan (7 lbs., 1 oz.). Everyday I look at my two little miracles, and I am so thankful…

The Kings tried to conceive for three years. After enduring major surgeries, unsuccessful treatments with oral medications, and a failed intrauterine insemination (IUI), they decided that IVF was their last hope. Dr. Donahue was confident that the procedure would work with the help of Bravelle™, a newer fertility treatment. The Kings achieved success with their first attempt. In her essay, Thalia speaks of her experience:

Sometimes I get caught up in the wonder of it all. Our beautiful daughter (Katherine Elizabeth) [has] just turned one and I can’t believe how incredibly lucky my husband and I are to have her in our lives … We were literally putting all of our eggs in one basket. I had to wait a few days before I could take the most important drug, the baby-making drug, the Bravelle™. As I was sitting on the chair holding the needle … I was saying, ‘do your magic, little drug.’ … A week later, after an ultrasound, we discovered [that] the drug had worked! We still remain in awe everyday as we watch her grow and learn. A friend asked me just today if I could remember what life was like without her. And I simply replied, ‘No, and I don’t care to remember.’

About Bravelle™ and Repronex™

Repronex™ (menotropins for injection, USP) is the only human menopausal gonadotropin (hMG) on the market in the U.S. and is approved for both subcutaneous and intramuscular administration.

Bravelle™ and Repronex™, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with Repronex™ and/ or Bravelle™ may result in multiple gestations.

About Ferring Pharmaceuticals

About Family Beginnings, PC

Family Beginnings, PC has provided advanced fertility care to patients in Central Indiana for the past nine years. Family Beginnings’ founding physician, James G. Donahue, M.D., is personally involved with all aspects of his patients care. In late 2002, the practice added a larger North side location with an on-site in vitro fertilization (IVF) laboratory, egg retrieval room and recovery beds. Family Beginnings is the only practice in central Indiana to offer IVF in an office-based setting where comfort, safety, convenience, and exceptional pregnancy rates are obtained. For more information, visit www.ivf-indiana.com.

# # #

For full prescribing information for Bravelle™ and/ or Repronex™, please contact Kelly Laban.

OAK BROOK FERTILITY CELEBRATES WITH ITS PATIENT NAMED AS WINNER OF FERRING'S MY LITTLE MIRACLE ESSAY CONTEST

Thu, 26 Feb 2009 17:01:31 +0000

Ferring Presents $1,000 to Local Honorable Mention Winner

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 x15 or KLaban@KLCpr.com

Jeff Burrows, Ferring Pharmaceuticals, presents Wendy and Doug Hurst, honorable mention winners of its My Little Miracle Essay Contest, with a $1,000 prize for their child, Hudson Robert, born with the help of Repronex™ (menotropins for injection, USP) - one of the Company’s fertility treatments.

Pictured from left to right: Doug Hurst; Hudson Robert Hurst; Wendy Hurst; and Jeff Burrows, Ferring Pharmaceuticals.

OAK BROOK, IL – November 30, 2004 – Oak Brook Fertility Center (OBFC) announced today that its patient, Wendy Hurst, and her husband, Doug, received a $1,000 honorable mention prize from Ferring Pharmaceuticals for their entry in the Company’s My Little Miracle Essay Contest. Their entry, A Little Help, chronicled the path to their son’s birth. The prize money will be deposited into an education fund for Hudson Robert, their two-year-old son born with the help of Repronex™ (menotropins for injection, USP) – one of Ferring’s fertility treatments. The presentation was made on November 29th at the OBFC’s office in Oak Brook.

“We are so excited and grateful to receive an honorable mention scholarship!” said Wendy Hurst. “Thanks for your part in helping us achieve our dream of becoming a family.”

“A healthy baby born after years of infertility is, indeed, the most wonderful ‘little miracle’ for the parents as well as for the entire staff at OBFC,” added W. Paul Dmowski, M.D., Ph.D., Medical Director, OBFC. “I commend Ferring Pharmaceuticals for recognizing this in their contest and would like to compliment Wendy and Doug on their award-winning essay.”

“Ferring is delighted to offer this program to help fertility patients contribute to their children’s future,” added Jeff Burrows, reproductive and endocrine specialist, Ferring Pharmaceuticals. “Ferring is committed to providing patients with safe, effective and affordable fertility treatments. The My Little Miracle Essay Contest is an extension of Ferring’s support of its patients.”

About the Hursts

The Hursts unsuccessfully tried to conceive for almost two years before they sought treatment. After a failed first attempt at conceiving with the help of fertility treatment, their physician, Dr. Dmowski, tried treatment with another type of medication. In the essay, Doug, Wendy’s husband, speaks of their experience:

He said ‘I love you Daddy’ on my work voice mail yesterday. Hudson is only 22 months old, so I suspect he had a little help from Mommy … you know, to at least dial the right number. Nothing wrong with a little help. We’ve been getting help every step of the way. The decision to have children was an easy one for us, but we were among a surprisingly large group who have high hopes for a family and lots of love to give but need a miracle to get there … We were ready for some help. After routine testing and a failed result …, [Dr. Dmowski] assured us, ‘With a little help from Repronex™, you will be pregnant within three months.’ A lofty claim, we thought. … it turned out that Repronex™ was the final piece of the puzzle for us. We were lucky enough to get immediate results. As fate would have it, getting pregnant in that first month turned out to be especially important. You see, Hudson arrived in time to meet my father who passed away exactly 23 days later after a long bout with cancer. Hudson is the joy of our lives. … P.S. Our second little ‘Repro Boy’ is on the way. We are planning on naming him Cooper when he arrives in February. We are hoping for a couple ‘Repro Girls’ in the future to balance things out.

**About Bravelle™ and Repronex™**

Repronex™ (menotropins for injection, USP) is the only human menopausal gonadotropin (hMG) on the market in the U.S. and is approved for both subcutaneous and intramuscular administration.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with Repronex™ and/ or Bravelle™ may result in multiple gestations.

About Ferring Pharmaceuticals

About Oak Brook Fertility Center

Oak Brook Fertility Center (OBFC) is a state-of-the-art medical facility fully equipped to diagnose and treat infertility problems and reproductive disorders involving male, female, or both partners. At OBFC, their In Vitro Fertilization Program is entirely office-based and one of the first such facilities in the country. Their success rates have been consistently above the national average and one of the highest in the Midwest. The Center provides comfortable, modern facilities that have been granted full accreditation by healthcare organizations. OBFC physicians are double-board certified (Obstetrics/ Gynecology and Reproductive Endocrinology/ Infertility) and are recognized nationally and internationally in the field of reproductive endocrinology. For more information about OBFC, please visit www.oakbrookfertility.com.

# # #

For full prescribing information for Bravelle™ and/ or Repronex™, please contact Kelly Laban.

LOCAL MAN WINS $5,000 FOR HIS 11-MONTH-OLD CHILDREN

Thu, 26 Feb 2009 17:01:31 +0000

Northville Resident Wins Runner-Up Prize in Ferring’s My Little Miracle Essay Contest

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 x15 or KLaban@KLCpr.com

Pictured: Evan (l) and Tyler (r), 11-month-old sons of John Doskocz, runner-up winner of Ferring Pharmaceutical’s My Little Miracle Essay Contest. John’s $5,000 prize will be placed in 529 education funds for Evan’s and Tyler’s future education.

Northville, MI – December 9, 2004 – John Doskocz, Northville resident, received a $5,000 runner-up prize from Ferring Pharmaceuticals for his entry in the Company’s My Little Miracle Essay Contest. John’s entry, How We Got to Our Dream Destination, chronicled the long path to his sons’ births. The prize money will be deposited into education funds for Evan and Tyler, his 11-month-old sons born with the help of
Bravelle™ (urofollitropin for injection, purified) and Repronex™ (menotropins for injection, USP) – two of Ferring’s fertility treatments.

“We thought that one double miracle this year was amazing with the birth of our twin boys Tyler and Evan. Now Ferring has not only contributed to their birth but also to their future,” said John Doskocz. “Our new family sincerely thanks you for another wonderful surprise in 2004.”

About the Doskoczs

After trying unsuccessfully to become pregnant for three years, the Doskoczs decided to seek treatment at the Colorado Center for Reproductive Medicine. The couple met with William B. Schoolcraft, M.D., who helped them through their fertility treatments. In his essay, John speaks of their experience:

Being unable to conceive for a long time is like being at an airport and being unable to get on any flight while those around you seem to be hopping on planes left and right to their dream destination. They want to tell you about their wonderful experience when they return and naturally are pulling out many photos of their trip to share with you. All the while they have no idea this is rubbing salt into your wound. With modern medicine, we [were] told that we could possibly conceive … So now we’re stuck at the airport, but are instructed we can maybe make our destination if we row a boat. It will take longer and require much more work, and there’s no guarantee [that] the boat won’t sink along the way. With really no other option … we grab our oars! … You have to have faith in yourself and faith in the products and process that the doctor has directed. … you don’t realize how many others have had to take the boat until you are out there rowing yourself. It’s good to know you’re not alone. … Well, our boat was as strong as our determination, and with the help of Bravelle™ and Repronex™, we have Tyler and Evan, our beautiful twin boys!!

About Bravelle™ and Repronex™

Bravelle™, a highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to two percent LH activity.

Bravelle™, administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression.

Bravelle™, administered SC in conjunction with hCG, is also indicated for multiple follicular development during ART cycles in patients who have previously received pituitary suppression. Repronex™ is the only human menopausal gonadotropin (hMG) on the market in the U.S. and is approved for both subcutaneous and intramuscular administration.

Bravelle™ (urofollitropin for injection, purified) and Repronex™ (menotropins for injections, USP), like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with
Repronex™ and/ or Bravelle™ may result in multiple gestations.

About Ferring Pharmaceuticals

# # #

For full prescribing information for Bravelle™ and/ or Repronex™, please contact Kelly Laban.

GEORGIA REPRODUCTIVE SPECIALISTS CELEBRATES WITH ITS PATIENT NAMED AS WINNER OF FERRING'S MY LITTLE MIRACLE ESSAY CONTEST

Thu, 26 Feb 2009 17:01:31 +0000

Ferring Presents $1,000 to Local Honorable Mention Winner

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 x15 or KLaban@KLCpr.com

Jeff Horne, reproductive and endocrine specialist, Ferring Pharmaceuticals, presents Kristi Pelot, honorable mention winner of its My Little Miracle Essay Contest, with a $1,000 prize for her children, Max and Jackson, born with the help of Repronex™ (menotropins for injection, USP) - one of the Company’s fertility treatments.

Pictured from left to right: Jeff Horne, Ferring Pharmaceuticals, Kristi Pelot holding Max, and Eric Scott Sills, M.D., holding Jackson.

ATLANTA – November 23, 2004 – Georgia Reproductive Specialists (GRS) announced today that its patient, Kristi Pelot, received a $1,000 honorable mention prize from Ferring Pharmaceuticals for her entry in the Company’s My Little Miracle Essay Contest. Kristi’s entry, Two Heartbeats, chronicled the path to her sons’ births. The prize money will be deposited into an education fund for Max and Jackson, her twenty-two-month-old sons born with the help of Repronex™ (menotropins for injection, USP) – one of Ferring’s fertility treatments. The presentation was made on November 22nd at GRS’s office in Atlanta.

“I am so thrilled to have been chosen as a winner in the My Little Miracle Essay Contest,” said Kristi Pelot. “We are so pleased that our twin boys have a good start to their educational futures! Thank you, Ferring Pharmaceuticals, for making our dreams of parenthood a reality!”

“Our entire team was elated to hear of yet another success story with Repronex™,” added Eric Scott Sills, M.D., GRS. “The fact that Ferring supports this type of educational fund for the babies conceived with such therapy is commendable.”

“Ferring is delighted to offer this program to help fertility patients contribute to their children’s future,” added Jeff Horne, reproductive and endocrine specialist, Ferring Pharmaceuticals. “Ferring is committed to providing patients with safe, effective and affordable fertility treatments. The My Little Miracle Essay Contest is an extension of Ferring’s support of its patients.”

About the Pelots

The Pelots unsuccessfully tried to conceive for three years and endured two early miscarriages before they sought treatment with a fertility specialist. The couple consulted Dr. Sills and began treatment. After one year of various treatment protocols, and in consultation with both Dr. Sills and another center physician, Mark Perloe, M.D., Kristi was prescribed a new treatment protocol with Repronex™. In her essay, Kristi, speaks of their experience:

‘I see one heartbeat … and … two heartbeats!’ said our doctor. ‘I thought one of the eggs had no yolk in it!’ I said. … My husband and I looked at each other incredulously. We were not only pregnant, we were pregnant with twins! A week before, an ultrasound had confirmed our home pregnancy test. One of the eggs had looked healthy, while the other did not. … On the way home from our doctor’s office, I stopped and bought a book on twins. We dubbed ‘Baby B’ the ‘Come-Back Kid,’ and he’s been determined ever since! … Our boys have completely changed our lives, and my husband and I are very proud of every little milestone they reach. … we know [that] we are truly blessed and very thankful for two healthy boys.

About Bravelle™ and Repronex™
Bravelle™ (urofollitropin for injection, purified), a highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to two percent LH activity. Bravelle™, administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression. Bravelle™, administered SC in conjunction with hCG, is also indicated for multiple follicular development during ART cycles in patients who have previously received pituitary suppression.

Repronex™ (menotropins for injection, USP) is the only human menopausal gonadotropin (hMG) on the market in the U.S. and is approved for both subcutaneous and intramuscular administration.

Bravelle™ (urofollitropin for injection, purified) and Repronex™, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including ovarian hyperstimulation syndrome (OHSS) (incidence of 6.0% and 3.5%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with
Repronex™ and/ or Bravelle™ may result in multiple gestations.

About Ferring Pharmaceuticals

About Georgia Reproductive Specialists
Georgia Reproductive Specialists (GRS) leads the region in reproductive research and applies medical science’s most advanced fertility technologies to provide the highest standards of patient-centered, reproductive healthcare. The staff at GRS, including infertility laboratory pioneer Michael Tucker, Ph.D., is focused on providing individualized, innovative solutions for reproductive challenges and infertility, specializing in in vitro fertilization, intracytoplasmic sperm injection and other assisted reproductive technologies. Fellowship-trained reproductive endocrinologists Dr. Susan C. Conway, Dr. Carolyn Kaplan, Dr. Mark Perloe and Dr. Eric Scott Sills, are experts in female and male disorders including polycystic ovary syndrome (PCOS), repeated pregnancy loss, menstrual disorders and azoospermia. GRS has three offices, Atlanta, Alpharetta and Decatur, to conveniently serve patients across Metro Atlanta. For more information about GRS, visit www.ivf.com.

# # #
For full prescribing information for Bravelle™ and/ or Repronex™, please contact Kelly Laban.

LOCAL FERTILITY PRACTICE CELEBRATES PATIENT NAMED AS WINNER OF FERRING'S MY LITTLE MIRACLE ESSAY CONTEST

Thu, 26 Feb 2009 17:01:31 +0000

Ferring Presents $1,000 to Honorable Mention Winner

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 or KLaban@KLCpr.com

Mike Seckler, eastern district manager, Ferring Pharmaceuticals, presents Joann Holmes, honorable mention winner of Ferring’s My Little Miracle Essay Contest, with a $1,000 prize to be deposited in an education fund for her son, Grayson Zinck-Holmes. Grayson was born with the help of Repronex™ (menotropins for injection, USP) - one of the Company’s fertility treatments.

Pictured from left to right: Christina R. Veit, M.D.; Mary, Joann’s partner, Joann Holmes holding Grayson; Mike Seckler, Ferring Pharmaceuticals.

Tarrytown, NY – November 30, 2004 – Christina R. Veit, M.D., announced today that her patient, Joann Holmes, received a $1,000 honorable mention prize from Ferring Pharmaceuticals for her entry in the Company’s My Little Miracle Essay Contest. Joann’s entry, My Little Miracle, chronicled the path to her son’s birth. The prize money will be deposited into an education fund for Grayson G. Zink-Holmes, her eight-month-old son born with the help of Repronex™ (menotropins for injection, USP) – one of Ferring’s fertility treatments. The presentation was made on November 29th at Dr. Veit’s office in Tarrytown.

“Ferring Pharmaceuticals helped to provide us with a wonderful future through the birth of our son,”said Joann Holmes. “Through this award, Ferring is now helping to provide for his future. We couldn’t be more grateful!”

“Our office was really excited to meet Joann’s new baby,”added Christina R. Veit, M.D. “Ferring’s generous program has helped Joann start to plan for Grayson’s education and we are happy to have been a part of bringing Joann and Ferring together.”

“Ferring is delighted to offer this program to help fertility patients contribute to their children’s future,”added Mike Seckler, eastern district manager, Ferring Pharmaceuticals. “Ferring is committed to providing patients with safe, effective and affordable fertility treatments. The My Little Miracle Essay Contest is an extension of Ferring’s support of its patients.”

About Joann Holmes

Joann Holmes and her partner, Mary, decided to seek fertility treatment in the Spring of 2003. Since Joann was over 40-years-old at the time they decided to seek treatment, she was concerned about her chances of successfully conceiving a child. They decided that Joann would carry their first child and Mary would carry their second. In her essay, written as a poem, Joann, speaks of their experience:

On the first of March two thousand and four, My little miracle arrived with a roar. With the sound of his voice and the look of his face,
Came a small piece of heaven right here in this place.

With his eyes big and blue and a heart pure as gold,
Our baby, our joy, is a wonder to hold. But let us go back and provide an account, Of our journey through fear, self pity and doubt.

We started our family late in the game, And were told that our chances were really quite lame. Saddened and troubled we reached out for hope, And thought that this might be the end of our rope.
Our research on how to proceed was a chore, A drug that could help us – could this be our cure? With hope on the rise and our prayers for the best, We started injections of Ferring’s Repronex™.

A few months had passed and one day we heard, It really has happened – we then spread the word. This wonderful news we could hardly believe, A drug called Repronex™ had helped us conceive!

When he arrived, our sweet little boy, Our hearts were filled with love and laughter and joy.
Our blessings are counted over again, And we share in a love that will never end.

Our story is one of thousands you see, Of all who’ve been helped to have a baby. This treatment is true and not just empirical, The proof is in seeing my little miracle!

Joann and Mary are expecting their second child in late May 2005.

About Bravelle™ and Repronex™

Bravelle™ (urofollitropin for injection, purified), a highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to two percent LH activity. Bravelle™, administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression.Bravelle™, administered SC in conjunction with hCG, is also indicated for multiple follicular development during ART cycles in patients who have previously received pituitary suppression.

Repronex™ (menotropins for injection, USP) is the only human menopausal gonadotropin (hMG) on the market in the U.S. and is approved for both subcutaneous and intramuscular administration.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with Repronex™ and/ or Bravelle™ may result in multiple gestations.

About Ferring Pharmaceuticals

About Christina R. Veit, M.D.
Christina R. Veit, M.D., is a board certified obstetrician gynecologist. Dr. Veit specializes in gynecology, reproductive endocrinology, fertility, polycystic ovarian syndrome (PCOS) and menopause. Services provided in Dr. Veit’s private practice include family planning; evaluation and treatment of PCOS, endometriosis, fibroids and couples with fertility concerns; laparoscopy; hysteroscopy; intrauterine insemination (IUI); and in vitro fertilization (IVF). The practice support staff consists of a registered nurse, a medical assistant, a board-certified sonographer and administrative personnel. For more information, visit www.veitmd.com or call (914) 631-1292.

# #

For full prescribing information for Bravelle™ and/ or Repronex™, please contact Kelly Laban.

FERRING SUPPORTS SYMPOSIUM ON OPTIMIZING ASSISTED REPRODUCTIVE TECHNOLOGY (ART)

Thu, 26 Feb 2009 17:01:31 +0000

Held at 60th Annual Meeting of the American Society for Reproductive Medicine

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 or KLaban@KLCpr.com

PHILADELPHIA - October 18, 2004 - Optimizing the ART Process Now and in the Future: From Gonadotropins to Enhanced Evaluation of Embryonic Development, a continuing education (CME) symposium supported by an unrestricted educational grant from Ferring Pharmaceuticals, was held today at the 60th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Philadelphia.

The symposium focused on technologies used in producing gonadotropins; protocol selection principles for women undergoing ovarian stimulation; active management of gonadotropin-stimulated cycles; and evolving technologies in laboratory procedures and embryo selection.

Comparison of Recombinant and Urinary Therapies
Recombinant and Urinary Gonadotropins: Comparison of Efficacy, Safety and Consistency was presented by Scott C. Chappel, PhD, Venture Partner, Apple Tree Partners, and former Chief Scientific Officer, Serono. Dr. Chappel compared recombinant and urinary gonadotropins on efficacy, safety and consistency. He concluded that urinary and recombinant therapies are equally effective, with no consensus on superiority. Dr. Chappel explained the purification and testing processes for both therapies, the collection process for urinary FSH and the production of recombinants from recombinant-derived cell banks.

“While there are safety concerns associated with the production of bulk material from cell banks and purifying material for recombinants, as well as from the collection of urinary gonadotropins, these processes are well-controlled, well-established and safe,” concluded Dr. Chappel.

“As for batch-to-batch consistency, it is virtually impossible to demonstrate any difference in consistency between urinary and recombinant gonadotropins as long as they are normalized by bioactivity using the same international standards with the same biological assay. There are many other variations that occur in this process–patient to patient, lab to lab, and cycle synchronization–that negate or diminish the importance of consistency within gonadotropins.”

Dr. Chappel also reviewed the evolution of hMG and recombinant therapies, pointing out that hMG therapy, the cornerstone of infertility treatment, has been used and studied for more than 40 years, and is the standard by which recombinant FSH is evaluated. Recombinant FSH was introduced ten years ago.

HMG-Supplied LH Activity
Human Menopausal Gonadotropin-Supplied Luteinizing Hormone Activity: Helpful, Harmful, or Necessary? was presented by Richard P. Marrs, MD, Managing Partner, California Fertility Partners. Dr. Marrs stated that GnRH antagonists can have a dose-dependent effect on luteinizing hormone (LH) levels, which correlates with cycle outcomes. He also stated that the use of FSH-only stimulation in cycles of profound LH suppression (<1.5 IU/L) has been demonstrated to have a negative impact on ART treatment. Dr. Marrs showed evidence demonstrating that in patients with severely depressed LH levels, controlled ovarian stimulation (COS) and pregnancy outcome are affected. There is no evidence that adding LH activity to COS has any negative clinical impact.

Dr. Marrs also concluded that in patients receiving highly purified human menopausal gonatropins (HP-hMG), ongoing pregnancy rates correlate with serum human chorionic gonadotropin (hCG) levels. His final remark was that hMG-induced increases in LH and hCG concentrations, which constitute the LH activity, appear to have a positive contribution to cycle outcomes.

Preimplantation Genetic Diagnosis
Richard Scott, MD, partner, Reproductive Medicine Associates of New Jersey discussed Preimplantation Genetic Diagnosis (PGD), a technique that can be used with in vitro fertilization (IVF) procedures to test embryos for genetic disorders prior to their transfer to the uterus.

Attending physicians will receive up to 1.5 CME credit hours in Category 1 toward the American Medical Association Physician’s Recognition Award. The ASRM is accredited by the Accreditation Council for Continuing Medical Education (ACCME).

Background on Human-Derived Hormones
The key differences in human-derived and genetically engineered infertility treatments are raw material sources and cost. Human-derived FSH treatments are highly-purified follitropins refined from the urine of postmenopausal women. By comparison, genetically engineered products are extracted from the secretions from Chinese hamster ovary cells that are cultured in fetal calf or other mammalian serum, and approximate human hormones. Both are manufactured in compliance with extremely strict standards (including viral inactivation and confirmatory testing), but human-derived products are generally less expensive than their genetically engineered counterparts.

About Ferring Pharmaceuticals
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex™ and Novarel™ in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

FERRING INTRODUCES BRAVELLE® WITH FIRST NEEDLE-FREE RECONSTITUTION DEVICE

Thu, 26 Feb 2009 17:01:31 +0000

Q·Cap™ Previewed at Annual ASRM Meeting

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 or KLaban@KLCpr.com

Ferring Pharmaceuticals’ Bravelle (urofollitropin for injection, purified) with Q·Cap™ (far right), is the first device enabling needle-free reconstitution (process of dissolving medication in diluent) of fertility treatments. It is for exclusive use with the Company’s human-derived fertility treatments and will be packaged with Bravelle™.

Philadelphia - October 18, 2004 - Ferring Pharmaceuticals introduced today the Q·Cap™, the first device enabling needle-free reconstitution (process of dissolving medication in diluent) of fertility treatments. It is for exclusive use with the Company’s human-derived fertility treatments and will be packaged with Bravelle™ (urofollitropin for injection, purified). The device allows user-friendly reconstitution of medication(s) in a single vial, in single or mixed protocols, simplifying preparation for injection, and eliminating product waste and accidental needle sticks. The Q·Cap™ was previewed at the 60th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Philadelphia, October 16-20, 2004.

“In a recent survey by the International Council on Infertility Information Dissemination (INCIID), 77% of the 537 in vitro fertilization (IVF) polled patients reported reconstitution as the most stressful part of IVF therapy,” said William Garbarini, Director of Marketing, Ferring Pharmaceuticals. “Part of that stress was specifically attributed to the use of needles. Since the Q·Cap™ is needle-free, it eliminates patients’ anxiety associated with needle use during this process and increases comfort levels, making patients more confident in their self-treatment while ensuring that the full prescribed medication dose is administered from the vial.”

The Q·Cap™ provides fast and easy reconstitution that is consistent with the traditional needle and syringe injection method that patients have become accustomed to and may need to use with other medications prescribed during their treatment cycle. It allows patients to easily withdraw the full contents of each vial needle-free. It does not interfere with the patient’s ability to withdrawal her full dose without wasting product.

The device can also be used with Ferring’s Repronex™ (menotropins for injection, USP) fertility treatment.

How Q·Cap™ Works
For reconstitution, the patient twists the Q·Cap™ onto the syringe, pushes the tip through the diluent vial’s rubber stopper, and pulls back on the plunger to remove the diluent. Next, the patient places the Q·Cap™ on the vial containing the Bravelle™ or Repronex™ powder, pushes the tip into the rubber stopper, then slowly injects the diluent into the vial and swirls the diluent and medication until the medication is dissolved. The solution can be used to dissolve up to six vials in one syringe.

The Q·Cap™ can be used to reconstitute medication(s) in one syringe regardless of protocol and allows the patient to administer only one injection per day. If more than one medication is required, the patient simply repeats the process with the additional vial(s) of medication(s) before attaching the injection needle to the vial. This improved reconstitution process reduces time required to educate patients since it mirrors the reconstitution process with the standard needle and syringe technique, eliminates accidental needle sticks and eliminates product waste.

“The Q·Cap™ is a new feature designed to make self-treatment with Bravelle™ easier and less stressful for patients,” said Dr. Richard T. Scott, Jr., Director and Managing Partner of Reproductive Medicine Associates of New Jersey. “Another benefit of the Q·Cap™ is that it requires only one injection in mixed protocols, whereas other devices require at least two. By using the Q·Cap™, different ratios of Bravelle™ and Repronex™ can be delivered in one syringe to meet individual patient needs.”

The Q·Cap™ will be commercially available in late 2004. For more information, complete instructions for use and a video demonstrating the reconstitution process with Q·Cap™ please visit www.ferringfertility.com.

About Bravelle™ and Repronex™

Bravelle™, a highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to two percent LH activity. Bravelle™, administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression. Bravelle™, administered SC in conjunction with hCG, is also indicated for multiple follicular development during ART cycles in patients who have previously received pituitary suppression.

Repronex™ is the only human menopausal gonadotropin (hMG) on the market and is approved for both subcutaneous and intramuscular administration.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with
Repronex™ and/ or Bravelle™ may result in multiple gestations.

SOCIETY FOR REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY ANNOUNCES FERRING PHARMACEUTICALS' SPONSORSHIP OF FELLOWS' RETREAT 2005-2007

Thu, 26 Feb 2009 17:01:31 +0000

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 or KLaban@KLCpr.com

Philadelphia – October 18, 2004 – The Society for Reproductive Endocrinology and Infertility (SREI) announced today that Ferring Pharmaceuticals will be the new sponsor of its annual educational Fellows’ Retreat Program from 2005 through 2007. The announcement was made by William Schlaff, M.D., president of SREI, at a reception hosted by Ferring at the Annual Meeting of the American Society for Reproductive Medicine in Philadelphia.

“We are grateful to Ferring for providing this welcome support for our annual Fellows’ Retreat over the next three years,” said Dr. Schlaff. “Ferring’s unrestricted educational grant enables SREI to provide an intensive educational forum for reproductive endocrinology fellows that complements their academic training.”

The Fellows’ Retreat has been held every August for the past 12 years. The program offers first- and third-year fellows an opportunity to focus on issues that are important to their career planning and development. Topics include aspects of their future practice environment, such as private practice versus academic setting; research or clinical practice; and how to balance work and personal life by making sound decisions for themselves and their families. The Retreat also provides fellows with the opportunity to meet junior faculty and senior leadership.

“We are delighted to partner with SREI to support the practice of reproductive endocrinology and the practical education of future REs,” said Wayne Anderson, president of Ferring Pharmaceuticals. “Now that these highly trained physicians are in the final stage of their basic medical education, they will benefit from the practical training provided at the retreat to prepare them for their future.”

ABOUT SREI
The Society for Reproductive Endocrinology and Infertility is made up of Obstetrician-Gynecologists with advanced education, research and professional skills in Reproductive Endocrinology & Infertility. These highly trained and qualified physicians treat Reproductive Disorders that affect children, women, men, the mature woman, and infertility in both men and women.

ABOUT FERRING PHARMACEUTICALS
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex™ and Novarel™ in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.

FERRING PRESENTS $10,000 GRAND PRIZE TO WINNER OF MY LITTLE MIRACLE ESSAY CONTEST

Thu, 26 Feb 2009 17:01:31 +0000

Contest Winner Announced at ASRM

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 or KLaban@KLCpr.com

PHILADELPHIA - October 18, 2004 - Ferring Pharmaceuticals, manufacturer of a family of fertility treatments, today announced that Jennifer and Stephen Lyon, of Overland Park, Kansas, are the grand prize winners of its My Little Miracle Essay Contest. Wayne Anderson, president of Ferring, presented the Lyons with a $10,000 check to be deposited in an education fund for their one-year-old daughters, Ella and Catherine, born with the help of Ferring’s Repronex™ (menotropins for injection, USP). The presentation was made on October 17 at the 60th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Philadelphia.

“Although it was a different kind of surprise, I think I was almost as shocked to hear that we won this contest as I was to hear we were expecting twins,” said Jennifer Lyon. “And here I was thinking that as a mother of three infants, being shocked was a thing of the past. The education fund is another wonderful gift from the company that has already made a priceless contribution to our miracle family.”

The My Little Miracle essay contest celebrated the births of children made possible through Ferring’s fertility treatments, Bravelle™ (urofollitropin for injection, purified) and Repronex™ (menotropins for injection, USP). Ferring awarded $25,000 in education funds to 12 winners from around the country.

The Contest Winners
The Lyons had tried to conceive unsuccessfully for almost three years when they turned to adoption to start a family. At the same time, Doctors Daniel L. Stewart and Dan L. Gehlbach at Reproductive Medicine & Infertility at Shawnee Mission Medical Center urged them to consider one more option–an intrauterine insemination (IUI) treatment cycle with Repronex™. They agreed and began treatment, but continued to pursue adoption. Six weeks after completing the required papers for adoption, the Lyons were notified that they had been chosen to be the parents of a young boy. Their joy was then doubled when they learned that Jennifer was pregnant–with twins. In her essay, Jennifer speaks of her experience:

“It’s a typical afternoon. Laundry piles everywhere. ‘Teddy Bear Picnic’ is on its fourteenth playing, as someone has hidden the stereo remote. Our twenty-month old, Jackson, donning one high-heeled shoe, is trying to perfect his summersault in the laundry. Fifteen month-old Ella, diaper self-removed, is on a naked mission to ‘love’ (a.k.a. torture) the cat, while her twin Catherine is on tiptoes pounding out a baby sonata on the piano. I can’t remember a time when this house was quiet or clean, and I don’t really care. … They climb everything in sight, know how to really shake it when provided with the right tunes, and give the best hugs know, to man and most furry creatures. They don’t realize they’re our miracles…but we do.”

John and Fiona Doskocz, of Northville, Michigan, are the runner-up winners and will receive a $5,000 education fund for their nine-month-old sons, Evan and Tyler. Ten honorable mention winners will each receive a $1,000 education fund for their children born with the help of Ferring’s fertility treatments.

About Bravelle™ and Repronex™

Repronex™ is the only human menopausal gonadotropin (hMG) on the market and is approved for both subcutaneous and intramuscular administration.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with Repronex™ and/ or Bravelle™ may result in multiple gestations.

WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD

Thu, 26 Feb 2009 17:01:31 +0000

Ferring Pharmaceuticals Announces My Little Miracle Essay Contest

Contact:

Kelly Laban
Kovak-Likly Communications
(203)762-8833 or KLaban@KLCpr.com

Ferring’s My Little Miracle contest is open to women who have been successfully
treated with Bravelle^{^®} (urofollitropin for injection), Repronex^{^®} (menotropins for injection, USP) or a combination of both. The contest celebrates the miracles of their children’s births and continues Ferring’s tradition of providing value to their patients through affordable fertility treatments by offering education funds for the winners’ children.

Ferring is also awarding a $5,000 education fund for the runner up and 10
honorable mention winners will each receive $1,000. All 12 winners will be featured in Ferring’s 2005 Year of Miracles calendar.

Essays should not exceed 400 words, must be written in English, include the
entrant’s name, address, phone number, and age, as well as the child(ren)’s name and age(s) and be submitted with a contest application and labeled photo. Entries must be postmarked or e-mailed by September 30, 2004. Winners will be announced at the 60th Annual Meeting of the American Society for Reproductive Medicine, October 16 - 20, 2004 at the Pennsylvania Convention Center in Philadelphia, PA.

For more details and a contest application visit www.ferringfertility.com,
www.ferringusa.com or call (203) 762-8833 and ask for the My Little Miracle Essay Contest representative.

Repronex^{^®} and Bravelle^{^®} , like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 3.5% and 6.8%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Both treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with Repronex^{^®} and/or Bravelle^{^®} may result in multiple gestations.

RESULTS OF EMBRACE* TRIALS PRESENTED AT THE PACIFIC COAST REPRODUCTIVE SOCIETY MEETING

Thu, 26 Feb 2009 17:01:31 +0000

First-Ever Systematic Evaluation of Mixed Protocols in IVF

Contact:

Marilyn Seiger
Kovak-Likly Communications
203.762.8833 or mseiger@klcpr.com

Rancho Mirage, CA – April 28, 2003 – Results of clinical trials evaluating the combined use of two human-derived infertility treatments in in vitro fertilization (IVF) – Bravelle^®, a follicle stimulating hormone (hFSH), and Repronex^®, a purified human menopausal gonadotropin (hMG), were presented at the 51st Annual Meeting of the Pacific Coast Reproductive Society in Rancho Mirage, CA, April 23 to 27, 2003. An oral presentation and one poster were presented.

“These studies add to a growing body of clinical evidence supporting the use of mixed protocols of LH and FSH in settings that reflect today’s clinical practice,” said William R. Keye, Jr., M.D., director of the Division of Reproductive Endocrinology and Infertility at William Beaumont Hospital in Royal Oaks, MI. “For example, the use of mixed protocols in IVF has increased dramatically during the past several years. We have undertaken the first-ever systematic evaluation of different mixed protocols, using a single daily dose mixed in the same syringe, in the older and younger patient.”

EMBRACE Trials
William Keye, M.D., lead investigator, presented results of the EMBRACE II study, which assessed the efficacy and safety of Bravelle and Repronex in continuous and sequential dose ratios, when combined in the same syringe and administered subcutaneously, once daily to patients ages 34 to 40 for controlled ovarian hyperstimulation (COH) in in vitro fertilization (IVF). Patients were randomized into three treatment groups and received gonadotropin stimulation (GS) for 15 days. Group A had a 1:1 FSH:hMG ratio throughout the study. Group B began with FSH only and then changed to a 1:1 ratio after stimulation day five. Group C had a 2:1 ratio that, after stimulation day five, was sequentially adjusted to 3:1, 4:1, or 5:1 as needed to a maximum FSH dose of 450 IU. When ultrasound showed three follicles with diameters of 16 mm and acceptable E2 levels , GS was stopped and hCG given the next day; oocytes were retrieved 34-36 hours later. The primary efficacy parameter was the number of oocytes retrieved.

“Across all treatment groups, there were no statistically significant differences in the total numbers of oocytes retrieved or safety results. The combination of human-derived FSH and hMG in the same syringe produced excellent live birth rates in all groups (Group A = 42.1%, Group B = 30.6%, Group C = 38.9%).”

Richard Marrs, M.D., lead investigator, presented results of the EMBRACE I study, which demonstrated similar results, using the same parameters in patients ages 18-33 years. There were however some differences associated with the 1:1 FSH:hMG treatment group where those patients used significantly less FSH during the study and had significantly higher E2 levels.

“These studies demonstrate the effectiveness of single daily subcutaneous doses of human-derived gonadotropins using varying dose ratios. There were no significant between-group differences in safety and efficacy, although a larger study is needed to conclude that the efficacy from the different ratios is equivalent,” said Richard P. Marrs, M.D., director of the Center for Reproductive Medicine at Santa Monica-UCLA Medical Center and partner of California Fertility Partners. “This study confirms previously published work showing that Bravelle and Repronex can be mixed in the same syringe without impacting the bioactivity of FSH and luteinizing hormone (LH)¹.”

About The Investigators
William R. Keye, Jr., M.D., director of the Division of Reproductive Endocrinology and Infertility at William Beaumont Hospital in Royal Oaks, MI, has 26 year of experience and is board certified in Reproductive Endocrinology and Obstetrics and Gynecology. Dr. Keye received his medical degree from the University of Minnesota Medical School and completed his residency training in obstetrics and gynecology at both the University of Minnesota and the University of California, San Francisco (UCSF). Dr. Keye completed a reproductive endocrinology research program at the University of Michigan, followed by a fellowship in reproductive endocrinology at UCSF. He previously served as the President of the American Society for Reproductive Medicine.

Richard P. Marrs, M.D., director of the Center for Reproductive Medicine at Santa Monica-UCLA Medical Center and partner of California Fertility Partners, is a board certified Reproductive Endocrinologist. He studied medicine and trained in Obstetrics and Gynecology in Texas before studying Reproductive Endocrinology at the University of Southern California (USC). While at USC, he developed one of the country’s first IVF programs. He is internationally recognized for his contributions to the development of IVF. Dr. Marrs serves on the boards of numerous medical and scientific organizations and is a prominent figure in the national and international infertility communities.

*Evaluation of Mixed Protocols with Bravelle and Repronex to Assess Clinical Efficacy

Bravelle and Repronex are registered trademarks of Ferring Pharmaceuticals Inc.

CLINICAL STUDY CONFIRMS EFFECTIVENESS OF FERRING'S NEW BRAVELLE® IN PRODUCING DONOR EGGS FOR IVF

Thu, 26 Feb 2009 17:01:30 +0000

Study appears in Today’s Therapeutic Trends

Contact:

Marilyn Seiger
Kovak-Likly Communications
203.762.8833 or mseiger@klcpr.com

SUFFERN, NY – February 10, 2003 – According to a new study published in the First Quarter 2003 issue of Today’s Therapeutic Trends, Bravelle^® (urofollitropin for injection, purified), a highly purified human-derived follicle-stimulating hormone (hFSH), administered subcutaneously (SC), is effective and well tolerated for inducing oocyte development in donors for use in in vitro fertilization (IVF) patients. The study also resulted in excellent rates of implantation and pregnancies. Bravelle^® was approved by the U.S. Food and Drug Administration (FDA) on May 6, 2002 for ovulation induction (OI) and on December 19, 2002 for IVF.

“This study confirms that Bravelle^® is effective for controlled ovarian hyperstimulation for IVF in oocyte donors, and that the resulting embryos can be successfully transferred to recipients, leading to high pregnancy rates without high multiple births,” said Kenneth B. Kashkin, M.D., vice president, medical and regulatory affairs. “Not only can the results help infertility specialists determine optimum stimulation protocols for their donor patients, but the study also contributes to Ferring’s comprehensive body of clinical research on current treatment approaches in assisted reproductive technology (ART).”

Study Design
Bravelle^® SC was tested for efficacy and safety in its ability to induce oocyte development in donors for IVF procedures in an open-label, single arm, multicenter trial in 39 donors, ages 21 to 33, and 39 recipients, ages 28 to 48. Bravelle^® SC was administered for up to 12 days in oocyte donors who were successfully down-regulated (achieved pituitary suppression). When patients produced at least three follicles with diameters ≥ 16 mm and estradiol levels were within acceptable limits, human chorionic gonadotropin (hCG) was administered, and oocytes were retrieved. A maximum of four embryos were transferred to each recipient.

The primary outcome measure was the mean number of oocytes retrieved for donor subjects. Secondary outcome measures included the mean daily and total dose of FSH, the mean number of days of gonadotropin stimulation, the percentage of subjects who received hCG and underwent oocyte retrieval, the mean peak serum E2 levels, and chemical, clinical and ongoing pregnancy rates. Safety was measured by the numbers of patients reporting adverse events.

Study findings
All 39 donors treated with Bravelle^® received hCG and underwent oocyte retrieval. The mean daily FSH dose was 239.7 ± 50.8 IU, and mean number of days of stimulation was 8.9 ± 1.3. The mean number of total oocytes and mature oocytes retrieved was 15.5 ± 7.9 and 12.3 ± 7.7. Oocytes of 38 subjects underwent fertilization and embryo transfer. The mean number of embryos transferred per recipient was 2.7 ± 0.89. Of the 38 recipients:

73.7% achieved chemical pregnancies;
63.2%, clinical pregnancies; and
55.3%, continuing pregnancies.

Thirteen recipients had singleton pregnancies, eight had twin pregnancies, and there were no other multiple pregnancies. The treatment was well tolerated, with nearly all adverse events in donors mild to moderate and of the nature expected with this class of medication. The data confirm that Bravelle^® produces predictable ovarian follicular growth and development in oocyte donors with excellent pregnancy rates in recipients.

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe Bravelle^®. Like all gonadotropins, Bravelle^® is a potent substance capable of causing mild to severe adverse reactions, including ovarian hyperstimulation syndrome (incidence of 6.8%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Like other products for ovarian stimulation, treatment with Bravelle^® may result in multiple gestations.

About Bravelle^®
Bravelle^®, a highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to 2 percent LH activity. Bravelle^® is marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones.

Bravelle^®, administered SC or IM in conjunction with hCG, is indicated for ovulation induction following pituitary suppression. Bravelle^®, administered SC in conjunction with hCG, is also indicated for multiple follicular development during ART cycles in patients who have previously received pituitary suppression.

Background on Human-Derived Hormones
The key differences in human-derived and genetically engineered infertility treatments are raw material sources and cost. Human-derived FSH treatments are highly purified follitropins refined from the urine of postmenopausal women. By comparison, genetically engineered products are extracted from the secretions from Chinese hamster ovary cells that are cultured in fetal calf or other mammalian serum, and approximate human hormones. Both are manufactured in compliance with extremely strict standards (including viral inactivation and confirmatory testing), but human-derived products are generally less expensive than their genetically engineered counterparts.

About Ferring
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle^®, Repronex^® and Novarel™ in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology and infertility. For more information, call 1-888-337-7464 or visit www.ferringusa.com.

FDA APPROVES BRAVELLE™ FOR IN VITRO FERTILIZATION

Thu, 26 Feb 2009 17:01:30 +0000

Clinical Trial Demonstrates State-of-the-Art Performance With Significantly Less Injection Site Pain Than Follistim

Contact:

Kelly Laban
Kovak-Likly Communications
203.762.8833 or Klaban@KLCpr.com

SUFFERN, NY – December 19, 2002 – Ferring Pharmaceuticals’ new infertility treatment Bravelle™ (urofollitropin for injection, purified), approved by the U.S. Food and Drug Administration (FDA) for ovulation induction following pituitary suppression on May 6, 2002, received FDA approval today for use in in vitro fertilization (IVF).
Bravelle™ is a highly purified, human-derived follicle-stimulating hormone (hFSH) administered by subcutaneous (SC) injection in IVF treatment cycles.

The new indication followed clinical evaluation demonstrating that Bravelle™ SC provides state-of-the-art performance, comparable in efficacy and safety to Follistim^® SC (recombinant follitropin beta) in IVF, with significantly less injection site pain.
Bravelle™ and Follistim were also comparable in mean number of stimulation days, number of vials used and estradiol levels measured during the treatment cycle.

“Bravelle™ is well suited to meet the needs of both physicians and patients,” said Kenneth B. Kashkin, M.D., vice president, medical and regulatory affairs. “Physicians can feel confident that Bravelle™ offers the predictability and clinical performance required by today’s IVF protocols, along with additional important patient benefits. In our clinical studies, patients using Bravelle™ reported significantly less injection site pain than those using Follistim. In addition, Bravelle™ is the most affordably priced product in its category, an important benefit since infertility treatment is generally not fully covered by insurance.”

Follistim (follitropin beta for injection) is a registered trademark of Organon Inc.

A Human-Derived FSH Proven as Effective as Genetically Engineered FSH

Bravelle™ was compared to Follistim in a randomized, assessor-blind, parallel group, multicenter trial in 120 patients undergoing controlled ovarian hyperstimulation for IVF. The pregnancy outcomes in patients receiving human chorionic gonadotropin (hCG) were equivalent for Bravelle™ SC and Follistim SC.¹

Study outcomes in patients receiving hCG	Bravelle™ SC (n=57)	Follitropin beta SC (n=59)
Oocytes retrieved	12.4	12.1
Clinical pregnancy	43.9%	45.8%
Continuing pregnancy	40.3%	45.8%
Live birth	26.3%	32.2%

A second prospective, parallel-group, multicenter, open-label trial in 118 patients undergoing controlled ovarian hyperstimulation for IVF was published in the June issue of Fertility and Sterility and showed that there were no significant differences in efficacy and safety between the treatment groups.²

Study outcomes in patients receiving hCG	Bravelle™ SC (n=56)	Follitropin beta SC (n=56)
Oocytes retrieved	14.3	13.6
Clinical pregnancy	46.4%	32.1%
Continuing pregnancy	44.6%	30.4%
Live birth	37.5%	25.0%

In both trials, patients experienced significantly less injection site pain with Bravelle™ compared with Follistim on the majority of treatment days.

Lowest Priced FSH Available
Based on wholesale acquisition cost, Bravelle™ is the most affordably priced product in its category, an important benefit since infertility treatment is generally not fully covered by insurance. In the two studies, patients used approximately 30 vials of medication during the treatment cycle. In this case, the projected savings with Bravelle™ would range from $447 to $520.

Number of Vials Utilized	Bravelle™	Gonal-F^{^®}	Follistim^{^®}	Difference in cost per number of vials utilized
1	$49	$64	$66	$15 - $17
10	$490	$639	$664	$149 - $174
20	$980	$1,278	$1,327	$298 - $347
30	$1,470	$1,917	$1,990	$447 - $520
40	$1,960	$2,556	$2,654	$596 - $694

Comparison based on lowest priced package. Dollars rounded to whole numbers. Gonal-F (follitropin alfa for injection) is a registered trademark of Serono Laboratories, Inc.

Bravelle™: The Natural Choice

Bravelle™ is a highly purified, human-derived follicle-stimulating hormone (hFSH) that is used to induce ovulation. In IVF, it is also used to control the timing of egg ripening and increase the chance of producing a substantial number of eggs.

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe Bravelle™. Like all gonadotropins, Bravelle™ is a potent substance capable of causing mild to severe adverse reactions, including ovarian hyperstimulation syndrome (incidence of 6.8%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Background on Human-Derived Hormones
The key differences in human-derived and genetically engineered infertility treatments are raw material sources and cost. Human-derived FSH treatments are highly purified follitropins extracted from the urine of postmenopausal women. By comparison, genetically engineered products are derived from the secretions from Chinese hamster ovary cells that are grown in fetal calf or other mammalian serum, and approximate human hormones. Both are manufactured in compliance with extremely strict standards (including viral inactivation and confirmatory testing), but human-derived products are generally less expensive than their genetically engineered counterparts.

About Ferring
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex^® and Novarel™ in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology and infertility.

For more information, call 1-888-337-7464 or visit www.ferringusa.com.

# # #

For full prescribing information contact Kelly Laban at 203-762-8833.

THE AMERICAN INFERTILITY ASSOCIATION, RESOLVE AND FERRING TEAM UP TO IMPROVE ACCESS TO INFERTILITY TREATMENT

Thu, 26 Feb 2009 17:01:30 +0000

Contact:
Kelly Laban
Kovak-Likly Communications
203.762.8833 or Klaban@KLCpr.com

TARRYTOWN, NY – November 11, 2002 – Ferring Pharmaceuticals, The American Infertility Association (AIA) and RESOLVE: The National Infertility Association today announced the launch of the Bravelle™ HEART Program. The Bravelle™ (urofollitropin for injection, purified) HEART Program will assist thousands of infertility patients by providing up to 25 percent of the medication used in an average ovulation induction treatment cycle free of charge.

“Infertility treatment can be costly and many insurance companies do not provide full coverage. We are delighted to partner with The American Infertility Association and RESOLVE to offer infertility patients greater access to the medication they need,” said Wayne Anderson, President, Ferring Pharmaceuticals. “Through the Bravelle™ HEART Program, we are able to offer physicians and their patients the benefits of our newest infertility treatment at a significant cost savings, helping patients reduce the financial strain incurred on the path to parenthood.”

“The United States is a patchwork quilt of haves and have-nots when it comes to insurance coverage for infertility treatment. Without insurance coverage, patients can be locked out of treatments they need to start a family. The Bravelle™ HEART Program represents the type of initiative that can have a significant impact on couples who may not pursue treatment or who may discontinue treatment prematurely because of cost,” said Pamela Madsen, Executive Director of The American Infertility Association. “The American Infertility Association commends Ferring for its ongoing efforts to provide effective and affordable treatment options for the infertility community.”

Bonny Gilbert, Acting Executive Director for RESOLVE added, “While public awareness of infertility has increased in the last decade, policymakers, employers and insurance companies have been slow to recognize infertility as a legitimate medical condition. This can place a great deal of financial pressure on couples that are already coping with the stress of infertility. We are pleased to work with Ferring to help offset the very real financial burden that infertility treatment can place on couples.”

About the Bravelle™ HEART Program

The Bravelle™ HEART (Helping Expand Access to Reproductive Therapy) Program provides infertility patients with five vials of Bravelle™ free of charge as part of a prescription for 20 vials or more. Bravelle™ HEART Program information packs are available by e-mail request at the following Web sites, www.americaninfertility.org or www.resolve.org.

About Bravelle™

Bravelle™, approved by the FDA on May 6, 2002, is a highly purified, human-derived follicle-stimulating hormone (hFSH) for the treatment of infertility. Bravelle™, in conjunction with hCG, is indicated for ovulation induction following pituitary suppression. Bravelle™, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (incidence of 8.2%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Like other products for ovarian stimulation, treatment with Bravelle may result in multiple gestations.

About The American Infertility Association

The American Infertility Association is a national organization dedicated to supporting women, men and families facing infertility and decisions related to family building and reproductive health–from prevention and treatment to social, psychological and financial concerns. Through educational symposia and forums, free publications, interactive media and advocacy for research funding and policy, The American Infertility Association serves as a lifetime resource for men, women and families needing reproductive information and support and to forward the causes of adoption and reproductive health. Contact The American Infertility Association toll free at 888-917-3777 or visit the Web site at www.americaninfertility.org.

About RESOLVE

RESOLVE: The National Infertility Association since 1974, is committed to helping people build their families by providing education, advocacy and support. RESOLVE assists people throughout the continuum of infertility from trying to conceive through treatment, adoption, pregnancy, parenting or the decision to live child-free. Each year, National RESOLVE and its network of more than 50 chapters across the U.S. provide support groups, educational meetings and advocate for insurance coverage for infertility and adoption. Contact the RESOLVE help line at 888-623-0744 or visit the RESOLVE Web site at www.resolve.org.

About Ferring

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex^® and Novarel^® in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 888-337-7464 or visit www.ferringusa.com.
# # #

For Bravelle™ full prescribing information contact Kelly Laban at 203.762.8833.

CLINICAL STUDY SUPPORTS IVF INDICATION FOR FERRING'S NEW BRAVELLE™ (urofollitropin for injection, purified)

Thu, 26 Feb 2009 17:01:30 +0000

Study appears in June issue of Fertility and Sterility

TARRYTOWN, NY – June 10, 2002 – According to a new study published in the June issue of Fertility and Sterility, Bravelle™ (urofollitropin for injection, purified), a highly purified human-derived follicle-stimulating hormone (hFSH), administered subcutaneously (SC) and intramuscularly (IM), is comparable in activity and tolerability to recombinant follitropin beta (Follistim SC) for in vitro fertilization (IVF). Bravelle™ was approved by the U.S. Food and Drug Administration (FDA) on May 6, 2002 for ovulation induction (OI) following pituitary suppression, a common step in the treatment of infertility. These and other data supporting the use of Bravelle™ in IVF are currently under review by the FDA.

“This study demonstrates that in IVF, premium-priced recombinant FSH showed no advantage in activity or tolerability over Bravelle™, a highly purified preparation of human-derived FSH,” said Wayne Anderson, president of Ferring Pharmaceuticals. “Bravelle™ is ideally suited to meet the needs of infertility specialists and their patients by providing an affordable treatment that combines human-derived hormone efficacy with recombinant hormone-like purity.”

Study Design
Bravelle™ SC, Bravelle™ IM and Follistim SC were compared in a randomized, open-label, parallel group, multicenter trial in 177 patients, ages 18 to 39, undergoing controlled ovarian hyperstimulation for IVF. Patients who were successfully down-regulated (achieved pituitary suppression) were randomized into three groups and received Bravelle™ SC (n=60), Bravelle™ IM (n=59) or Follistim (n=58) once daily (225 IU to a maximum of 450 IU) for up to twelve days. Subsequently, human chorionic gonadotropin (hCG) was administered to the 167 patients who qualified, based on the number and size of ovarian follicles and serum E₂ levels, and oocytes were retrieved.

The primary measure of activity was the mean number of oocytes retrieved per patient in each treatment group. Secondary variables included peak mean serum E₂ levels, the percentage of cycles with oocyte retrieval, embryo transfer and chemical, clinical and ongoing pregnancy rates. Safety was measured by the numbers of patients reporting adverse events.

Study Findings

During the course of treatment, there were no significant differences among the treatment groups in mean follicle diameters, serum E₂ levels, the total number of oocytes retrieved, the number of oocytes fertilized and the number of embryos transferred. While not statistically significant, the number of patients with clinical and continuing pregnancies and live births was consistently greater in the Bravelle™ SC group than in the Bravelle™ IM or Follistim SC groups.

Percentage of patients achieving:	Bravelle™ SC (n=56)	Bravelle™ IM (n=55)	Follistim (n=56)
Clinical pregnancy	46.4%	34.5%	32.1%
Continuing pregnancy	44.6%	34.5%	30.4%
Live birth	37.5%	29.1%	25.0%

Results showed that all three treatments were well tolerated, but Bravelle™ SC and IM caused significantly less injection site pain than Follistim (p<.001).

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe Bravelle™. Like all gonadotropins, Bravelle™ is a potent substance capable of causing mild to severe adverse reactions, including ovarian hyperstimulation syndrome (incidence of 6/73 in OI, 17/282 in all NDA studies), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

About Bravelle™

Bravelle™, a new highly purified human-derived follicle-stimulating hormone (hFSH) for infertility treatment, contains 75 IU of FSH and up to 2% LH activity and is available for both subcutaneous (SC) and intramuscular (IM) injection. Bravelle™ is marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones.

Bravelle, in conjunction with human chorionic gonadotropin, is indicated for ovulation induction following pituitary suppression. Ferring’s application seeking additional indications for Bravelle™ in infertility treatment, is currently under FDA review.

Background on Human-Derived Hormones

The key differences in human-derived and genetically engineered infertility treatments are raw material sources and cost. Human-derived FSH treatments are highly purified follitropins refined from the urine of postmenopausal women. By comparison, genetically engineered products are extracted from the secretions from Chinese hamster ovary cells that are cultured in fetal calf or other mammalian serum, and approximate human hormones. Both are manufactured in compliance with extremely strict standards (including viral inactivation and confirmatory testing), but human-derived products are generally less expensive than their genetically engineered counterparts.

About Ferring

Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex^® and Novarel™ in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 1-888-337-7464 or visit www.ferringusa.com.

FDA APPROVES BRAVELLE™ (urofollitropin for injection, purified) FERRING\’S NEW HUMAN-DERIVED FOLLICLE-STIMULATING HORMONE FOR INFERTILITY TREATMENT

Thu, 26 Feb 2009 17:01:30 +0000

New Highly Purified Alternative To Genetically Engineered Infertility Treatments

CONTACT:
Marilyn Seiger
Kovak-Likly Communications
203.762.8833
mseiger@klcpr.com

TARRYTOWN, NY – May 6, 2002 – Ferring Pharmaceuticals, a world leader in naturally occurring protein hormones, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Bravelle™ (urofollitropin for injection, purified), a highly purified, human-derived follicle-stimulating hormone (hFSH) for the treatment of infertility. Bravelle™, in conjunction with human chorionic gonadotropin, is indicated for ovulation induction following pituitary suppression.

“With the introduction of Bravelle™, Ferring has expanded its family of human-derived hormones to include a highly purified, well-tolerated hFSH with proven efficacy in ovulation induction, a critical step in many infertility treatment protocols,” said Wayne Anderson, president of Ferring Pharmaceuticals. “Based on the fact that recombinant technology has shown no meaningful advantage in either efficacy or safety in the clinic, Ferring remains committed to the development of human-derived products in order to seek improvements in ovarian stimulation protocols. Ferring has submitted an application to the FDA seeking additional indications for Bravelle™ in infertility treatment. This application, which is supported by additional clinical studies, brings the total number of patients studied to 577. This application is currently under review by the FDA.”

A Human-Derived FSH Proven as Safe and Effective as Genetically Engineered FSH
Bravelle™ was compared to follitropin beta, a recombinant FSH, in a prospective, parallel group, multicenter trial in 111 oligo-anovulatory patients undergoing ovulation induction. Patients underwent pituitary suppression with a GnRH agonist prior to being randomized to Bravelle™ SC, Bravelle™ IM or follitropin beta SC. Results showed that there were no significant differences in efficacy and safety between the treatment groups.

Percentage of patients achieving:	Bravelle™ SC(n=26)	Follitropin beta SC(n=35)
Ovulation	96.1%	85.7%
Clinical pregnancy	34.6%	31.4%
Continuing pregnancy	34.6%	28.6%
Live birth	34.6%	17.1%

In addition to the studies supporting the new drug application, Ferring has recently completed two Phase 3B clinical trials involving 24 centers. These trials evaluated the use of Bravelle™ together with Repronex^® (mixed protocol), Ferring’s human menopausal gonadotropin, in the same syringe, in two age groups. The first study evaluated the use of a mixed protocol in 108 women ages 18 to 33 years; the second trial evaluated 120 women ages 34 to 40 years. This is the first time a prospective, systematic clinical evaluation of single daily dose mixed protocols has been conducted anywhere in the world.

Bravelle™: The Natural Choice
Bravelle™ is affordably priced, an important benefit since infertility treatment is generally not fully covered by insurance. It is available for both subcutaneous and intramuscular injection. Most patients prefer SC administration because it is more convenient and causes less discomfort. Added Anderson, “Bravelle™ is ideally suited to meet the needs of infertility specialists and their patients by providing an affordable solution that combines human-derived hormone efficacy with recombinant hormone-like purity.”

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe Bravelle™. Like all gonadotropins, Bravelle™ is a potent substance capable of causing mild to severe adverse reactions, including ovarian hyperstimulation syndrome (incidence of 8.2%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Background on Human-Derived Hormones
The key differences in human-derived and genetically engineered infertility treatments are raw material sources and cost. Human-derived FSH treatments are highly purified follitropins extracted from the urine of postmenopausal women. By comparison, genetically engineered products are derived from the secretions from Chinese hamster ovary cells that are cultured in fetal calf or other mammalian serum, and approximate human hormones. Both are manufactured in compliance with extremely strict standards (including viral inactivation and confirmatory testing), but human-derived products are generally less expensive than their genetically engineered counterparts.

About Ferring
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex^® and Novarel^® in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 1-888-337-7464 or visit www.ferringusa.com.

# # #

For full prescribing information contact Kelly Laban at 203-762-8833.

FERRING PHARMACEUTICALS PRESENTS DATA ON NEW INFERTILITY TREATMENTS AT THE PACIFIC COAST REPRODUCTIVE SOCIETY MEETING

Thu, 26 Feb 2009 17:01:29 +0000

CONTACT:
Marilyn Seiger
Kovak-Likly
Communications
203-762-8833

Rancho Las Palmas, CA – April 22, 2002 – Results of clinical trials evaluating Ferring Pharmaceuticals’ infertility treatments– a human-derived follicle stimulating hormone (hFSH) and a purified human menopausal gonadotropin (hMG), which are currently under investigation–were presented at the 50th Annual Pacific Coast Reproductive Society Meeting in Rancho Las Palmas, CA, April 17 to 21, 2002. Four clinical abstracts and two posters were presented.

“These new clinical studies reflect Ferring’s commitment to broadening the existing body of knowledge in the field of infertility, while also providing meaningful data that reflect current treatment trends,” said Wayne Anderson, president of Ferring Pharmaceuticals Inc. “As specialists in the development of human-derived hormone medications, we look forward to offering physicians even greater treatment flexibility when we receive approval of our new hFSH – the fourth addition to our family of human-derived hormones.”

Same Syringe Mixed Protocol with Diluent
Ferring’s hFSH and purified hMG were tested to determine if the bioactivities of FSH and LH contained in the two treatments are altered after reconstituting them in the same diluent and mixing them in the same plastic syringe.

“This is the first time that FSH and hMG mixed in the same syringe has been tested using sophisticated bioassays,” said Mahendra DeSilva, Ph.D., Ferring’s manager of Professional Services. “Mixed protocols for ovarian stimulation are widely-used, and often combine FSH and hMG in the same syringe to decrease the number of daily injections. Once approved, infertility specialists will be able to mix Ferring’s hFSH and purified hMG in the same syringe with the assurance that the bioactivity of FSH and LH remains unchanged.”

Separate low, medium and high dose bioassays were performed in duplicate, comparing Ferring’s hFSH, purified hMG and FSH and LH Reference Standards. The study demonstrated that Ferring’s hFSH and purified hMG can be reconstituted in 0.9% sodium chloride and combined in the same syringe with no alterations in the bioactivity of FSH or LH.

Ferring’s Purified hMG Comparative Study
Ferring’s purified hMG was evaluated in a prospective, randomized, parallel group, open-label, multicenter study that compared purified hMG administered subcutaneously (SC) and intramuscularly (IM) to Repronex administered SC in patients undergoing in vitro fertilization. The primary measure of efficacy was the number of oocytes retrieved. Results were positive and were described in detail in posters presented at the meeting.

About Repronex and Ferring
Repronex is the only human menopausal gonadotropin (hMG) approved for both subcutaneous and intramuscular administration. It is also the most frequently prescribed hMG. Repronex, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (incidence of 3.5%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe Repronex.

Ferring Pharmaceuticals Inc., headquartered in Tarrytown, NY, is part of the Ferring Group, a privately owned, international biopharmaceutical company that specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 1-888-337-7464 or visit the Ferring Web site at www.ferringusa.com.

FERRING PHARMACEUTICALS LAUNCHES NEW WEB SITE OFFERING INFORMATION ON INFERTILITY TREATMENT

Thu, 26 Feb 2009 17:01:29 +0000

Web site launched at 57th Annual American Society for Reproductive Medicine (ASRM) Meeting in Orlando

Contact: Andrea Thornton Kovak-Likly Communications (203) 762-8833

ORLANDO, FL - October 24, 2001 - Ferring Pharmaceuticals announced today the launch of a new Web site that provides both consumers and professionals with comprehensive information on infertility and its treatment. The new site, www.ferringfertility.com, launched at the 57th annual American Society for Reproductive Medicine (ASRM) meeting in Orlando, FL, provides exclusive access to educational information developed by the ASRM. The site includes, and will be regularly updated with, educational materials on infertility, commonly used treatments and tips on understanding health insurance coverage and managing costs.

An additional resource on the Web site is an online patient support network called FerringCare. Individuals who currently use Ferring products can access the network to obtain patient support such as package inserts and step-by-step instructions for drug administration. FerringCare was also designed to offer infertility professionals exclusive Web sites customized to meet their patients’ specific needs.

“For the more than six million individuals in the U.S. affected by infertility, the medical process can be both stressful and overwhelming,” said Wayne Anderson, President, Ferring Pharmaceuticals. “Our goal is to meet our patients’ needs by providing them with educational resources, ongoing support and highly effective, high purity products.”

Additional highlights of the Web site include:
* Infertility information: offers tips such as Managing Costs, Understanding Health Insurance Coverage and Investigating Your Infertility Coverage; supplies detailed information on Ferring’s products.
* Resources: provides online access to educational materials developed by the ASRM such as a glossary of terms and Understanding Infertility; provides professionals with practice-customized patient information tools and information on upcoming events such as seminars, symposiums and referral events.
* Ferring Pharmaceuticals Inc., headquartered in Tarrytown, NY, is part of the Ferring Group, a privately owned, international biopharmaceutical company that specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 1-888-337-7464 or visit the Ferring Web site at www.ferringusa.com.

# # #

FERRING PHARMACEUTICALS HONORED BY THE AMERICAN INFERTILITY ASSOCIATION

Thu, 26 Feb 2009 17:01:29 +0000

CONTACT:
Marilyn Seiger Kovak-Likly Communications 203-762-8833

NEW YORK - October 24, 2001 – Ferring Pharmaceuticals, an international biopharmaceutical company that specializes in infertility treatments, received a “Family Building Award” from the American Infertility Association (AIA), an education and advocacy organization for women and men concerned about family building. The Award was presented at the AIA’s second annual benefit, the Kokopelli Ball, held on October 4, 2001 at the Pierre Hotel in New York City.

“The American Infertility Association is delighted to present our 2001 Family Building Award to Ferring Pharmaceuticals, who is greatly responsible for decreasing the cost of gonadotropins, thereby increasing the possibility of infertility treatment to more patients,” said Pamela Madsen, executive director of the AIA. Madsen and Karen R. Hammond, M.S.N., C.R.N.P., AIA chair, presented the award to Jason H. Nestor, executive director of sales, and Enyde Polesuk, national field sales director of Ferring Pharmaceuticals.

“We thank the AIA for this esteemed industry award, which recognizes Ferring’s contribution to the treatment of infertility,” said Nestor, executive director of sales. “We like to think of ourselves as a patient advocacy company, providing patients with educational resources, ongoing support and effective, high-quality products at a reasonable price.”

Ferring Pharmaceuticals markets Repronex^® (menotropins for injection USP), for patients undergoing ovulation induction or in vitro fertilization for infertility. Repronex is the lowest-cost human menopausal gonadotropin* (HMG) and the first HMG approved for subcutaneous administration. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe Repronex.

The American Infertility Association is a national organization headquartered in New York City that provides education, support and advocacy for women and men facing decisions related to family building, reproductive health, preventive health and menopause. The mission of the AIA is to serve as a lifetime resource that helps people make informed choices about their reproductive status and treatment, and forwards the causes of adoption and reproductive health through advocacy, education, awareness building and research funding. For more information, call 1-888-917-3777.

# # #

*based on wholesale acquisition cost.

FERRING INITIATES LANDMARK CLINICAL TRIALS TO EVALUATE OPTIMAL DRUG PROTOCOL FOR IVF TREATMENT

Thu, 26 Feb 2009 17:01:29 +0000

FOR IMMEDIATE RELEASE CONTACT: Marilyn Seiger Kovak-Likly Communications 203/762-8833 First-ever Evaluation of Combination Therapy in U.S.

Tarrytown, NY, February 28, 2001 – Ferring Pharmaceuticals, which specializes in human-derived hormones for infertility treatment, is conducting two clinical trials to investigate the optimal dose and ratio of two hormones used to stimulate the development of multiple eggs in in vitro fertilization (IVF). This is the first time a prospective, systematic clinical evaluation of single daily dose mixed protocols has been conducted anywhere in the world. Findings from the study will help infertility specialists fine-tune the ovarian stimulation protocols used in assisted reproductive technology.

The clinical trials compare combinations of Ferring’s new human-derived follicle stimulating hormone (hFSH), which is currently under investigation, and Repronex^® (menotropins for injection, USP), the most frequently prescribed human menopausal gonadotropin (HMG). Repronex contains equal amounts of FSH and luteinizing hormone (LH), which work both independently and synergistically to support follicular development and prepare the follicle and oocyte for ovulation.

“These first-ever studies are particularly relevant given our new understanding of the role of LH in ovulation induction,” said William Keye, M.D., investigator and director of the Division of Reproductive Endocrinology and Infertility at William Beaumont Hospital in Royal Oaks, MI. “We are finding that for many of our patients, returning to a protocol that includes HMG and FSH results in improved pregnancy rates. The results of these trials will help infertility specialists fine-tune ovarian stimulation protocols used in in vitro fertilization, improving a patient’s chance of a successful outcome.”

These studies will add important information to the growing body of evidence supporting the potential importance of LH for optimal follicle stimulation. In the November 2000 issue of Human Reproduction1, an authoritative clinical review by international experts, challenges the efficacy of recent gonadotropin treatments of FSH only compared to a dual treatment regimen of FSH and LH, which mimics the physiology of normal human follicular development.

Ferring’s two prospective, randomized, three-arm, parallel-group multicenter studies are being conducted with approximately 300 patients undergoing IVF-ages 18-33 at 17 centers and ages 34-40 at 12 centers. The studies will evaluate and compare the subcutaneous efficacy, safety and treatment toleration of a once-daily injection of Ferring’s human-derived FSH combined with Repronex in various continuous and sequential dose ratios. Following down regulation, a patient will be randomized into one of three treatment groups, with an assigned ratio of gonadotropins, which will be administered for five days. Doses will then be individualized for up to 15 days. The primary determinant of efficacy will be the mean number of oocytes retrieved. Secondary variables are the number of embryos transferred, peak mean serum E2 levels, and chemical, clinical and ongoing pregnancy rates.

“These studies will bring, for the first time, welcome insights into the clinical efficacy of mixed protocols for both younger and older women,” said Wayne Anderson, president of Ferring Pharmaceuticals Inc. “The addition of Ferring’s human-derived FSH medication will give physicians greater dosing flexibility with a highly purified modern gonadotropin treatment.” About Repronex and Ferring

Repronex is the only human menopausal gonadotropin (hMG) approved for both subcutaneous and intramuscular administration. It is also the lowest-cost gonadotropin* and most frequently prescribed hMG2. Repronex, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (incidence of 3.5%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe Repronex.

Euflexxa

WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD

FERRING PHARMACEUTICALS AND GENE SECURITY NETWORK PARTNER TO TEST ADVANCED PREIMPLANTATION GENETIC DIAGNOSIS (PGD) TECHNOLOGY

DEGARELIX (FIRMAGON®) VS LEUPROLIDE (LUPRON DEPOT®) IN PATIENTS WITH ADVANCED PROSTATE CANCER: FURTHER ANALYSIS FROM A PHASE III PIVOTAL TRIAL

RESEARCH COMPARES MENOPUR® WITH rFSH IN GNRH ANTAGONIST IVF CYCLES

RECENTLY PUBLISHED STUDY DEMONSTRATES PHARMACOKINETIC ADVANTAGES OF ENDOMETRIN® OVER CRINONE® FOR PROGESTERONE SUPPLEMENTATION

FERRING PHARMACEUTICALS ANNOUNCES TRADE NAME FIRMAGON® (degarelix for injection) FOR ADVANCED PROSTATE CANCER TREATMENT

FERRING PHARMACEUTICALS UNVEILS SIX-MONTH EFFICACY DATA FOR EUFLEXXA® FOR THE TREATMENT OF OSTEOARTHRITIS KNEE PAIN

FERRING PHARMACEUTICALS LAUNCHES PHASE IIIB TRIAL OF DEGARELIX AS INTERMITTENT THERAPY

FERRING PHARMACEUTICALS AND RESOLVE: THE NATIONAL INFERTILITY ASSOCIATION JOIN TOGETHER TO LAUNCH NURSE LIAISON PROGRAM

NEW APPROACH TO PROGESTERONE SUPPLEMENTATION IN ART REVEALED IN RECENTLY PUBLISHED WHITE PAPER

THRIVING FERRING TO OPEN NEW SITE -PHARMACEUTICAL IS EXPANDING LOCALLYSan Diego Union-TribuneFebruary 10, 2009

FERRING SUPPORTS A ROUNDTABLE DISCUSSION ABOUT COLLABORATIVE INFERTILITY CARE BETWEEN REPRODUCTIVE ENDOCRINOLOGISTS AND OBGYNS

FERRING PHARMACEUTICALS ANNOUNCES IMMEDIATE AVAILABILITY OF DEGARELIX FOR THE TREATMENT OF ADVANCED PROSTATE CANCER

FERRING PHARMACEUTICALS ANNOUNCES THREE STUDENT WINNERS OF TERRY MCMORROW SCHOLARSHIPS

FDA APPROVES FERRING PHARMACEUTICALS' DEGARELIX (generic name) FOR TREATMENT OF ADVANCED PROSTATE CANCER

WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD

FERRING REPORTS ON ENDOMETRIN® PRESENTATIONS AT PACIFIC COAST REPRODUCTIVE SOCIETY ANNUAL MEETING

COMPARATIVE STUDY SHOWS SAFER, MORE CONTROLLED STIMULATION WITH MENOPUR® THAN GONAL-f® IN OVULATION INDUCTION

NATIONWIDE SURVEY FINDS ONLY 30 PERCENT OF PATIENTS UNDERGOING INFERTILITY TREATMENT ARE ABLE TO ADMINISTER THEIR MEDICATIONS WITH ONE INJECTION PER DAY

FERRING PHARMACEUTICALS ANNOUNCES EUFLEXXA™ LABELING EXTENDED TO INCLUDE ROOM TEMPERATURE STORAGE

WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD

FERRING PHARMACEUTICALS ANNOUNCES BRUCE JENNER AS NATIONAL SPOKESPERSON FOR EUFLEXXA™

HEAD-TO-HEAD STUDY SHOWS EUFLEXXA™ HAS GREATER TOLERABILITY COMPARED TO SYNVISC® FOR OSTEOARTHRITIS KNEE PAIN

FERRING PHARMACEUTICALS ANNOUNCES LAUNCH OF EUFLEXXA™ FOR OSTEOARTHRITIS KNEE PAIN

FERRING PHARMACEUTICALS OBTAINS RIGHTS TO EUFLEXXA™

WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD

FERRING PHARMACEUTICALS APPOINTS OLIVIER DELANNOY AS VICE PRESIDENT, INFERTILITY BUSINESS UNIT

FERRING PHARMACEUTICALS APPOINTS WILLIAM GARBARINI AS SENIOR DIRECTOR OF MARKETING

FERRING PHARMACEUTICALS ANNOUNCES LAUNCH OF NEW TREATMENT FOR INFERTILITY

MICHAEL SECKLER APPOINTED NATIONAL SALES DIRECTOR FOR FERRING PHARMACEUTICALS

LOCAL WOMAN WINS $1,000 FOR HER 19-MONTH-OLD SON

FAMILY BEGINNINGS CELEBRATES WITH ITS PATIENTS NAMED AS WINNERS OF FERRING'S MY LITTLE MIRACLE ESSAY CONTEST

OAK BROOK FERTILITY CELEBRATES WITH ITS PATIENT NAMED AS WINNER OF FERRING'S MY LITTLE MIRACLE ESSAY CONTEST

LOCAL MAN WINS $5,000 FOR HIS 11-MONTH-OLD CHILDREN

GEORGIA REPRODUCTIVE SPECIALISTS CELEBRATES WITH ITS PATIENT NAMED AS WINNER OF FERRING'S MY LITTLE MIRACLE ESSAY CONTEST

LOCAL FERTILITY PRACTICE CELEBRATES PATIENT NAMED AS WINNER OF FERRING'S MY LITTLE MIRACLE ESSAY CONTEST

# #

FERRING SUPPORTS SYMPOSIUM ON OPTIMIZING ASSISTED REPRODUCTIVE TECHNOLOGY (ART)

FERRING INTRODUCES BRAVELLE® WITH FIRST NEEDLE-FREE RECONSTITUTION DEVICE

SOCIETY FOR REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY ANNOUNCES FERRING PHARMACEUTICALS' SPONSORSHIP OF FELLOWS' RETREAT 2005-2007

FERRING PRESENTS $10,000 GRAND PRIZE TO WINNER OF MY LITTLE MIRACLE ESSAY CONTEST

WIN A $10,000 EDUCATION FUND FOR YOUR MIRACLE CHILD

RESULTS OF EMBRACE* TRIALS PRESENTED AT THE PACIFIC COAST REPRODUCTIVE SOCIETY MEETING

CLINICAL STUDY CONFIRMS EFFECTIVENESS OF FERRING'S NEW BRAVELLE® IN PRODUCING DONOR EGGS FOR IVF

FDA APPROVES BRAVELLE™ FOR IN VITRO FERTILIZATION

THE AMERICAN INFERTILITY ASSOCIATION, RESOLVE AND FERRING TEAM UP TO IMPROVE ACCESS TO INFERTILITY TREATMENT

CLINICAL STUDY SUPPORTS IVF INDICATION FOR FERRING'S NEW BRAVELLE™ (urofollitropin for injection, purified)

FDA APPROVES BRAVELLE™ (urofollitropin for injection, purified) FERRING\’S NEW HUMAN-DERIVED FOLLICLE-STIMULATING HORMONE FOR INFERTILITY TREATMENT

FERRING PHARMACEUTICALS PRESENTS DATA ON NEW INFERTILITY TREATMENTS AT THE PACIFIC COAST REPRODUCTIVE SOCIETY MEETING

FERRING PHARMACEUTICALS LAUNCHES NEW WEB SITE OFFERING INFORMATION ON INFERTILITY TREATMENT

FERRING PHARMACEUTICALS HONORED BY THE AMERICAN INFERTILITY ASSOCIATION

FERRING INITIATES LANDMARK CLINICAL TRIALS TO EVALUATE OPTIMAL DRUG PROTOCOL FOR IVF TREATMENT

THRIVING FERRING TO OPEN NEW SITE -
PHARMACEUTICAL IS EXPANDING LOCALLY
San Diego Union-Tribune
February 10, 2009